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Background: Mechanical chest compression devices may help to maintain high-quality cardiopulmonary
resuscitation (CPR), but little evidence exists for their effectiveness. We evaluated whether or not the
introduction of Lund University Cardiopulmonary Assistance System-2 (LUCAS-2; Jolife AB, Lund, Sweden)
mechanical CPR into front-line emergency response vehicles would improve survival from out-of-hospital
cardiac arrest (OHCA).
Objective: Evaluation of the LUCAS-2 device as a routine ambulance service treatment for OHCA.
Design: Pragmatic, cluster randomised trial including adults with non-traumatic OHCA. Ambulance dispatch
staff and those collecting the primary outcome were blind to treatment allocation. Blinding of the ambulance
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staff who delivered the interventions and reported initial response to treatment was not possible. We also
conducted a health economic evaluation and a systematic review of all trials of out-of-hospital mechanical
chest compression.
Setting: Four UK ambulance services (West Midlands, North East England, Wales and South Central),
comprising 91 urban and semiurban ambulance stations. Clusters were ambulance service vehicles, which
were randomly assigned (approximately 1 : 2) to the LUCAS-2 device or manual CPR.
Participants: Patients were included if they were in cardiac arrest in the out-of-hospital environment.
Exclusions were patients with cardiac arrest as a result of trauma, with known or clinically apparent pregnancy,
or aged < 18 years.
Interventions: Patients received LUCAS-2 mechanical chest compression or manual chest compressions
according to the first trial vehicle to arrive on scene.
Main outcome measures: Survival at 30 days following cardiac arrest; survival without significant
neurological impairment [Cerebral Performance Category (CPC) score of 1 or 2].
Results: We enrolled 4471 eligible patients (1652 assigned to the LUCAS-2 device and 2819 assigned to
control) between 15 April 2010 and 10 June 2013. A total of 985 (60%) patients in the LUCAS-2 group
received mechanical chest compression and 11 (< 1%) patients in the control group received LUCAS-2.
In the intention-to-treat analysis, 30-day survival was similar in the LUCAS-2 (104/1652, 6.3%) and manual
CPR groups [193/2819, 6.8%; adjusted odds ratio (OR) 0.86, 95% confidence interval (CI) 0.64 to 1.15].
Survival with a CPC score of 1 or 2 may have been worse in the LUCAS-2 group (adjusted OR 0.72,
95% CI 0.52 to 0.99). No serious adverse events were noted. The systematic review found no evidence
of a survival advantage if mechanical chest compression was used. The health economic analysis showed
that LUCAS-2 was dominated by manual chest compression.
Limitations: There was substantial non-compliance in the LUCAS-2 arm. For 272 out of 1652 patients
(16.5%), mechanical chest compression was not used for reasons that would not occur in clinical practice.
We addressed this issue by using complier average causal effect analyses. We attempted to measure CPR
quality during the resuscitation attempts of trial participants, but were unable to do so.
Conclusions: There was no evidence of improvement in 30-day survival with LUCAS-2 compared with
manual compressions. Our systematic review of recent randomised trials did not suggest that survival or
survival without significant disability may be improved by the use of mechanical chest compression.
Future work: The use of mechanical chest compression for in-hospital cardiac arrest, and in specific
circumstances (e.g. transport), has not yet been evaluated.
TriaI registration: Current Controlled Trials ISRCTN08233942.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 21, No. 11.
See the NIHR Journals Library website for further project information.
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Plain English summary
The main treatment for people who suffer a cardiac arrest out of hospital is cardiopulmonary resuscitation(CPR), whereby blood circulation is maintained by repeatedly compressing the chest. Maintaining
high-quality CPR is very difficult, as people performing it tire and become less effective. Mechanical devices
may be more effective than people at providing chest compression, as they do not tire, ensure that every
compression is of the required depth and frequency and can operate in difficult conditions, such as in a
moving ambulance.
In this study, we evaluated a mechanical chest compression device called LUCAS-2 (Lund University
Cardiopulmonary Assistance System-2; Jolife AB, Lund, Sweden); this was introduced into ambulance
services in the UK several years ago, but it is not yet known whether or not it improves survival. Four UK
ambulance services took part in the study.
Vehicles were randomly allocated to carry a LUCAS-2 device or no LUCAS-2 device. If the vehicle carried a
LUCAS-2 device it was used to provide chest compressions for all cardiac arrests for which resuscitation
was attempted. If there was no LUCAS-2 device, manual chest compression was used. A total of 418
vehicles were included in the study and 4471 cardiac arrest patients were recruited. We recorded how
many patients survived to 30 days after their cardiac arrest and how many survived without significant
disability.
We found that there was no clear advantage of using the LUCAS-2 device. Survival was not improved and
slightly more survivors who were treated with the LUCAS-2 device had significant disability. An economic
analysis of the costs and benefits found that using the LUCAS-2 device was not as cost-effective as
standard cardiac arrest treatment.
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Scientific summary
Background
Chest compression is one of the crucial components of cardiopulmonary resuscitation (CPR). However, it is
known that it is difficult to maintain adequate depth and frequency of compressions, reducing the patient’s
chances of survival. Mechanical chest compression devices have been proposed as a potential solution, as
they can provide compressions of standard depth and frequency indefinitely, do not tire and can be used in
situations in which manual chest compression is difficult. In this trial we evaluated use of the LUCAS-2 device
(Lund University Cardiopulmonary Assistance System-2; Jolife AB, Lund, Sweden), which was introduced into
UK ambulance services several years ago without any evidence of effectiveness.
Objectives
1. To conduct a pragmatic, cluster randomised trial of the LUCAS-2 device compared with standard
manual chest compression for patients experiencing an out-of-hospital cardiac arrest.
2. To conduct an economic evaluation to estimate the cost-effectiveness of the LUCAS-2 device.
3. To perform a systematic review to combine the results of the current trial with those of other recent
trials of mechanical chest compression.
Methods
Study design
The design was a cluster randomised controlled trial (RCT), with ambulance service vehicles [ambulances
and rapid response vehicles (RRVs)] as the units of randomisation. Four UK ambulance services took part.
An economic evaluation was also conducted and we performed a systematic review to synthesise the
results of this and other recent randomised trials of mechanical chest compression.
Outcomes
Primary
1. Survival to 30 days post cardiac arrest.
Secondary
1. Survived event (survival to hospital).
2. Survival to hospital discharge.
3. Survival to 3 and 12 months.
4. Health-related quality of life at 3 and 12 months [Short Form questionnaire-12 items (SF-12)].
5. Neurological outcome at discharge from hospital [as measured via the Cerebral Performance Category
(CPC) scale with a score of 1 or 2 vs. 3–5].
6. Neurological outcome at 12 months (as measured via the Mini Mental State Examination).
7. Anxiety and depression at 12 months (as measured via the Hospital Anxiety and Depression Scale).
8. Post-traumatic stress at 12 months (as measured via the Post-Traumatic Stress Disorder Civilian Checklist).
9. Hospital length of stay.
10. Intensive care length of stay.
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Inclusion criteria
Patients were included if they were in cardiac arrest, if they were out of hospital, if resuscitation was
attempted and if they were attended by a trial vehicle. Exclusions were cardiac arrest due to trauma,
patients with a known or clinically apparent pregnancy and patients known to be or apparently aged
< 18 years.
Randomisation and treatment
Cardiac arrests were identified from routine ambulance service records. Patients were automatically
included in the trial if they met the inclusion criteria.
Data collection
Data were collected by research paramedics from ambulance service records. Deaths were identified from
ambulance services and routine UK NHS data via the Health and Social Care Information Centre. Surviving
patients were contacted for consent for follow-up and, if consent was given, they were visited at 3 and
12 months post cardiac arrest.
Analysis
We performed an intention-to-treat (ITT) analysis and, because of lower-than-expected compliance in the
LUCAS-2 arm, complier average causal effect (CACE) analyses. For the CACE analyses, we classified cases
of non-compliance into those that would happen in normal clinical practice (e.g. device malfunction,
location too restricted to use the LUCAS-2 device) and those that were specific to the context of the trial.
Economic evaluation
The economic evaluation assessed the cost-effectiveness of use of the LUCAS-2 device. It consisted of two
complementary sets of analyses: a within-trial analysis over the 12-month trial period and a decision-analytic
model that was constructed to extrapolate the results over the expected lifetime of the trial participants.
The cost-effectiveness analyses were conducted from the NHS and Personal Social Services perspective. The
analyses report cost per incremental quality-adjusted life-year of LUCAS-2 compared with usual care (manual
chest compression). Data from various sources were combined to estimate costs and treatment benefits,
including trial case report forms, large data sets (i.e. Hospital Episode Statistics, Intensive Care National Audit
and Research Centre data), self-completed patient questionnaires and data extracted from the literature.
Systematic review
We searched for randomised trials evaluating mechanical chest compression (using any device) published
since 1990 (search date February 2015). Data were extracted by two authors and meta-analyses conducted
using Review Manager software version 5.3 (RevMan, The Cochrane Collaboration, The Nordic Cochrane
Centre, Copenhagen, Denmark). Outcomes were return of spontaneous circulation, survival of event,
survival to discharge from hospital or 30 days and survival with good neurological outcome (measured by
CPC or modified Rankin Scale).
Results
We enrolled 4471 eligible patients (1652 assigned to the LUCAS-2 group and 2819 assigned to the
control group) between 15 April 2010 and 10 June 2013. Nine hundred and eighty-five (60%) patients in
the LUCAS-2 group received mechanical chest compression and 11 (< 1%) patients in the control group
received LUCAS-2 treatment. In the ITT analysis, 30-day survival was similar in the LUCAS-2 [104 (6.3%) of
1652 patients] and manual CPR groups [193 (6.8%) of 2819 patients; adjusted odds ratio (OR) 0.86, 95%
confidence interval (CI) 0.64 to 1.15]. Survival with a CPC score of 1 or 2 was worse in the LUCAS-2 group
(adjusted OR 0.72, 95% CI 0.52 to 0.99). No serious adverse events were noted. The systematic review
found no evidence that mechanical chest compression was superior to manual. The economic analysis
consistently showed that treatment with the LUCAS-2 device was more costly and less effective than manual
CPR, although differences in mean costs and outcomes between both treatment arms were fairly small.
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These results were obtained both in the within-trial analysis and in the analysis that modelled lifetime costs
and outcomes. When missing data were handled by multiple imputation, estimated costs were higher in
both arms, but the incremental cost-effectiveness ratios also indicated that manual CPR dominates LUCAS-2.
Conclusions
The trial, systematic review and economic evaluation all found that there was no evidence that mechanical
chest compression using LUCAS-2 was superior to standard manual chest compression.
Trial registration
This trial is registered as ISRCTN08233942.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Introduction
Description of condition
Definition
Cardiac arrest is defined as the cessation of cardiac mechanical activity, as confirmed by the absence of
signs of circulation.1 The majority of cardiac arrests outside a hospital occur as a result of cardiac causes
(e.g. ischaemic heart disease, myocardial infarction, arrhythmia). Other causes of cardiac arrest include
trauma, submersion, drug overdose, asphyxia, exsanguination or other medical causes (e.g. stroke,
pulmonary embolus).1,2
There are three different mechanisms through which cardiac arrest occurs – the development of an
arrhythmia that leads to loss of cardiac output [ventricular fibrillation (VF) or ventricular tachycardia (VT)],
insufficient cardiac contraction to generate a cardiac output, pulseless electrical activity (PEA) and a failure
of the electrical conduction system of the heart (asystole).3
The manifestations of cardiac arrest are dramatic: within seconds of it occurring the blood supply to the
brain and vital organs ceases. The victim loses consciousness and the process of cell death commences.
There is a narrow window of opportunity (minutes) during which, if the heart can be restarted, the victim
may be successfully resuscitated. The longer the victim remains in cardiac arrest, the worse the outcome
and if attempts at restarting the heart are either delayed or unsuccessful then death will occur.
Chain of Survival
The Chain of Survival (Figure 1) describes a series of steps that need to be in place to optimise the chances
of survival from out-of-hospital cardiac arrest (OHCA).4
Early access
The first link in the chain is early access, which highlights the importance of identifying a patient at risk of
cardiac arrest (e.g. someone suffering from an acute myocardial infarction) or someone who has sustained
a cardiac arrest (identified by the loss of consciousness and absence of normal breathing) and getting a
trained advanced life support (ALS) team to them as rapidly as possible.
High-quality cardiopulmonary resuscitation
The second link in the Chain of Survival is early cardiopulmonary resuscitation (CPR). CPR is the combination
of chest compressions and ventilations and is optimally started by those who are initially at the scene of the
FIGURE 1 The Chain of Survival. Reprinted from Jerry Nolan, Jasmeet Soar, Harald Eikeland. The Chain of Survival.
Resuscitation (2006), 71;270–1 with permission from the Resuscitation Council (UK) and Laerdal Medical.
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collapse. This is known as bystander CPR. Bystander CPR increases the odds of survival by 1.23 [95%
confidence interval (CI) 0.71 to 2.11] in the studies with the highest baseline survival rates and by 5.01
(95% CI 2.57 to 9.78) in the studies with the lowest baseline rates.5 When the emergency services arrive on
scene they will take over CPR. Current resuscitation guidelines highlight the importance of high-quality CPR
for ensuring optimal outcomes from cardiac arrest.6 High-quality CPR is defined as CPR that ensures that an
adequate chest compression depth is achieved (5–6 cm), the compression rate is 100–120 per minute,
interruptions are minimised and the chest is allowed to recoil between chest compressions.
Evidence supporting the importance of high-quality CPR is observational: there are no randomised trials
evaluating different compression parameters. Nevertheless, high-quality CPR appears to be important to
outcomes.7 Experimental studies show a linear increase in cardiac output and coronary perfusion pressure with
increasing compression depths.8,9 Observational studies in humans found improved shock success10 and better
return of spontaneous circulation (ROSC) rates and long-term survival with deeper chest compressions.11,12
Faster chest compression rates (> 100 minutes) are associated with improved survival13–15 and ensuring that the
chest is allowed to recoil between sequential chest compressions also appears to be important.16
Interruptions in CPR are harmful.17 A particularly critical time to minimise interruptions to CPR is around the
time of attempted defibrillation. Prolonged pre-shock and peri-shock interruptions in CPR reduce the
chances of shock success10 and survival.18
Early defibrillation
Approximately one-quarter of OHCA in the UK occurs as a result of an arrhythmia: either VF or VT. These
rhythms are referred to as shockable rhythms, as the arrhythmias may be terminated and cardiac function
restored by the successful delivery of defibrillator shocks. The time from the onset of VF/VT to the delivery
of a shock is critical to shock success and chances of survival. For every 60–90 seconds that a shock is
delayed, the chance of survival falls by approximately 10%.19
If a defibrillator is immediately available at the scene of a cardiac arrest, defibrillation should be attempted
without delay. Where there is a delay in initiating CPR, there is a theoretical rationale that providing CPR
before a shock improves coronary perfusion and thereby the chances of achieving sustained ROSC.20
This concept was evaluated by the Resuscitation Outcomes Consortium in a cluster randomised trial that
compared early analysis [30–60 seconds of emergency medical services (EMS)-administered CPR before
initial rhythm analysis] with later analysis (180 seconds of CPR, before the initial electrocardiographic
analysis).21 The primary outcome was survival to hospital discharge with satisfactory functional status
[a modified Rankin Scale (mRS) score of ≤ 3, on a scale of 0–6, with higher scores indicating greater
disability]. The study21 enrolled 9933 patients (5290 to early analysis and 4643 to late analysis), but found
no difference in outcomes (cluster-adjusted difference of –0.2%, 95% CI –1.1% to 0.7%).
Post hoc analyses found that for ambulance services with baseline VF survival of < 20%, ‘analyse late’
compared with ‘analyse early’ was associated with a lower chance of favourable functional survival
(3.8% vs. 5.5%; OR 0.67, 95% CI 0.50 to 0.90). Conversely, in ambulance services with VF survival of
> 20%, ‘analyse late’ was associated with a higher likelihood of favourable functional survival than
‘analyse early’ (7.5% vs. 6.1%; OR 1.22, 95% CI 0.98 to 1.52).22
In the UK, the Joint Royal College Ambulance Liaison Committee (JRCALC) recommended that defibrillation
should not be delayed to allow for a set period of predefibrillation CPR. In practical terms, this means that
when an ambulance crew arrive at the scene of a cardiac arrest they will start CPR while the defibrillator/
monitor is attached. Once attached, rhythm analysis and, if indicated, defibrillation should take place
without further delay.
Post-resuscitation care
The return of a spontaneous circulation marks the start of the post-resuscitation care phase of treatment.23
Unless the arrest has been relatively brief, most patients who achieve a ROSC will have an obtunded
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consciousness level, necessitating admission to intensive care. The focus of the post-resuscitation care phase
of treatment is upon stabilising cardiac function to prevent a further arrest and minimising the consequences
of the cardiac arrest on neurological outcome. This involves the use of targeted temperature management,
avoidance of hyperglycaemia and cardiac reperfusion treatments. Most post-resuscitation care treatments are
initiated following arrival in the emergency department and in the intensive care unit (ICU).
Incidence and burden of disease
Data from NHS England indicate that UK NHS ambulance services attend approximately 60,000 cardiac
arrests each year; of those arrests attended, resuscitation is attempted in just less than half (28,000
cases).24 Approximately 25% achieve an initial ROSC. However, only approximately one-third of those
who achieve a ROSC survive to go home from hospital; thus, the overall survival to discharge rate is
approximately 8%. The burden of disease is high, with an estimated 460,000 potential years of life lost,
270,000 of which are working years of life lost.
Functional survival after cardiac arrest is generally good, with the majority of those surviving doing so with
a favourable neurological outcome.25 Survivors may experience post-arrest problems, including anxiety,
depression, post-traumatic stress and difficulties with cognitive function.26
Despite the annual death toll exceeding that of dementia, stroke or lung cancer, there has been relatively
little investment in research into this lethal condition. This has created a relatively weak evidence base
compared with other diseases (e.g. there are 50-fold more trials per 10,000 deaths from myocardial
infarction than deaths from cardiac arrest). A review of the National Institute for Health Research (NIHR)
cardiovascular portfolio identified only 4 of 624 studies related to cardiac arrest. Until recently, the pattern
was similar in the USA.27
Existing evidence
At the time of initiating the PARAMEDIC (prehospital randomised assessment of a mechanical compression
device in OHCA) trial, there were no large published randomised controlled trials (RCTs) evaluating the
LUCAS-2 (Lund University Cardiopulmonary Assistance System-2; Jolife AB, Lund, Sweden) device. A
systematic review of the literature in 201228 identified 16 studies investigating the LUCAS-2 device. Four of
the studies were animal studies and 12 were human studies. Of the 12 human studies, one was a RCT and
11 were observational studies using either a cohort or before-or-after design (Figure 2).
The main finding of this review was that the existing evidence about the use of the LUCAS device is
inconclusive. The animal studies tended to provide evidence that the LUCAS-2 device improved
physiological end points, although the results were not consistent across studies.
Studies involving humans similarly lack consistency in the direction of benefit compared with harm. We
chose not to perform any meta-analyses because of observed heterogeneity, varying study design and the
high risk of bias in most of the included studies.
We concluded that the evidence base is insufficient for making any recommendations about the routine
use of the LUCAS-2 device in clinical practice.
This conclusion is similar to the International Liaison Committee for Resuscitation Consensus on Science
and Treatment’s recommendation,20 which advised that:
. . . there are insufficient data to support or refute the use of LUCAS-2 CPR instead of manual CPR.
It may be reasonable to consider LUCAS-2 CPR to maintain continuous chest compression while
undergoing computed tomography (CT) scan or similar diagnostic studies, when provision of manual
CPR would be difficult.
Deakin et al.20
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Rationale for intervention
Because of the problems with manual chest compression, several mechanical devices have been proposed.
These have potential advantages: they are able to provide compressions of a standard depth and frequency
for long periods without interruption or fatigue and they free emergency medical personnel to attend to
other tasks.
The LUCAS-2 is a mechanical device that provides automatic chest compressions. It delivers sternal
compression at a constant rate, to a fixed depth, by a piston with the added feature of a suction cup that
helps the chest return back to the normal position. It compresses 100 times per minute to a depth of
4–5 cm. It is easy to apply, stable in use, relatively light in weight (7.8 kg) and well adapted to use
during patient movement on a stretcher and during ambulance transportation. The device is Conformité
Européenne (CE) marked and has been on the market in Europe since 2002.
Detailed descriptions of the device and experimental data from animal studies showing increased cardiac
output and cortical cerebral flow compared with manual standardised CPR have been published.35,38
The LUCAS-2 device was introduced into a small number of ambulance services in the UK several years ago,
despite the absence of evidence of its effectiveness from randomised trials.39 It was subsequently withdrawn
from routine use by several of the services because of lack of evidence about safety and efficacy and is now
used only under restricted conditions. In the absence of evidence of clinical effectiveness or cost-effectiveness
and the presence of some concerns regarding safety, the JRCALC, in discussion with the Department of Health,
identified the need for large-scale clinical trials to evaluate the device.40 Until such studies are completed, no
further new purchases of the device are recommended by the JRCALC. A briefing note commissioned by the
National Institute for Health and Care Excellence (NICE) concluded that ‘there is therefore an urgent need to
evaluate this technology to discover whether it is effective and cost-effective in improving survival after cardiac
arrest’. The need for a definitive trial is reinforced in the International Liaison Committee for Resuscitation’s
analysis of knowledge gaps in resuscitation.41
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FIGURE 2 Forest plot from Gates et al.’s28 systematic review of studies examining the LUCAS-2 device.
M–H, Mantel–Haenszel; RR, risk ratio. Reproduced from Heart, Gates S, Smith JL, Ong GJ, Brace SJ, Perkins GD, 98,
908–13, 2012 with permission from BMJ Publishing Group Ltd.
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Chapter 2 Trial design and methods
Trial design
The PARAMEDIC trial was a pragmatic, cluster randomised trial, with ambulance service vehicles as the
unit of randomisation, comparing mechanical chest compression using the LUCAS-2 device with standard
manual chest compression, for patients in OHCA. The trial protocol has been published elsewhere.42
The trial was undertaken in partnership with four NHS ambulance services (West Midlands, North East
England, Welsh Ambulance Service and South Central). These organisations serve a total population of
13 million, spread over 62,160 km2. Vehicles were randomly allocated before the start of recruitment to
carry the LUCAS-2 device (LUCAS-2 arm) or not (manual compression arm).
We chose to use a cluster randomised design because of costs and concerns that an individually
randomised design would have a substantial risk of contamination among the manual compression arm.
With individual randomisation, all vehicles taking part in the trial would have to carry a LUCAS-2 device
and there would be a strong possibility that it would be used for patients who were allocated to manual
compression, especially if the perception of paramedics was that the LUCAS-2 device made chest
compression easier and allowed them to carry out other tasks more effectively.
Objectives
Primary objective
To evaluate the effect on mortality of using the LUCAS-2 device rather than manual chest compression
during resuscitation by ambulance clinicians (paramedics, technicians, emergency care assistants, etc.) after
OHCA at 30 days after the event.
Secondary objectives
To evaluate the effects of LUCAS-2 treatment on survival to 12 months, the cognitive and neurological
outcomes of survivors and the cost-effectiveness of the LUCAS-2 device.
Selection of trial sites
The NHS organisations that delivered the trial were ambulance trusts. Initially (at the time of the funding
application), we anticipated that three trusts would participate covering the West Midlands, Wales and
Scotland. However, the Scottish Ambulance Service withdrew from the trial before the start of recruitment
because its legal team was not happy with the research contract. The North East Ambulance Service and
South Central Ambulance Service subsequently joined the trial.
Outcome measures
Primary outcome
Survival to 30 days post cardiac arrest.
Secondary outcomes
l Survived event (sustained ROSC, with spontaneous circulation until admission and transfer of care to
medical staff at the receiving hospital).
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l Survival to hospital discharge (the point at which the patient is discharged from the hospital acute care
unit regardless of neurological status, outcome or destination).
l Survival to 3 and 12 months.
l Health-related quality of life (HRQL) at 3 and 12 months [Short Form questionnaire-12 items (SF-12)43
and EuroQol-5 Dimensions (EQ-5D)].44
l Neurologically intact survival to 3 months [survival with a Cerebral Performance Category (CPC)45 score of
1 or 2].
l Cognitive outcome at 12 months [as measured via the Mini Mental State Examination (MMSE)].46
l Anxiety and depression at 12 months [as measured via the Hospital Anxiety and Depression
Scale (HADS)].47
l Post-traumatic stress at 12 months [as measured via the post-traumatic stress disorder (PTSD) Civilian
Checklist (PCL-C)].48
l Hospital length of stay.
l Intensive care length of stay (see Appendix 1).
The outcomes defined by the Utstein convention1 for reporting outcomes from cardiac arrest are reported,
as well as long-term follow-up at 12 months. We did not measure the incidence of injuries resulting from
CPR, for three reasons: first, they are of little importance unless they result in differences in more substantive
outcomes such as survival or duration of hospitalisation; second, they are difficult to measure and classify
and may not be detected reliably; and, third, organising injury data collection from a large number of
hospitals was felt to add significant organisational complexity to the trial, for little benefit.
The CPC score is a 5-point scale for describing the neurological outcome after cardiac arrest and is
recommended by the Utstein guidelines.1 There is a generally accepted split into good neurological
outcome (CPC score of 1 or 2) and poor outcome (CPC score of 3–5). The definitions of the categories are:
l CPC 1 Good cerebral performance: conscious, alert, able to work.
l CPC 2 Moderate cerebral disability: conscious, sufficient cerebral function for independent activities of
daily life. Able to work in sheltered environment.
l CPC 3 Severe cerebral disability: conscious, dependent on others for daily support because of impaired
brain function. Ranges from ambulatory state to severe dementia or paralysis.
l CPC 4 Coma or vegetative state: any degree of coma without the presence of all of the brain death criteria.
l CPC 5 Brain death.
However, recent studies have demonstrated that this score may be insensitive to some of the more subtle,
but nevertheless important, longer-term neurocognitive and functional impairments that are experienced
by survivors of cardiac arrest.49,50 The spectrum of impairment of HRQL following cardiac arrest includes
memory and cognitive dysfunction, affective disorders and PTSD.48 The number of patients who are
expected to survive to hospital discharge was anticipated to be in the region of 200–300, which allowed
more intensive follow-up. We used four clinical outcome measures: the SF-12 is a standard quality-of-life
measure that is short and easy to complete. The PTSD PCL-C48 is a 17-item questionnaire measuring the
risk of developing PTSD and has been used in previous studies as a good surrogate for the clinical
diagnosis of PTSD, which would require a face-to-face interview by a suitably trained professional.
The HADS47 is a 14-item self-administered questionnaire, which has been previously used successfully to
measure affective disorders in those surviving cardiac arrest.51 The MMSE measures cognitive impairment.52
In addition, the EQ-5D44 was used as a health utility measure for the health economic analysis.
Inclusion/exclusion criteria
Eligibility for clusters
All vehicles that were in service at each participating ambulance station, eligible to attend patients and could
carry the device were included in the trial and randomised to one of the trial arms before the start of recruitment.
TRIAL DESIGN AND METHODS
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To maximise the efficiency of the trial, recruitment was concentrated predominantly in urban areas,
where each vehicle would attend a higher number of cardiac arrests per year. This avoided the costs of
supporting clusters in rural areas that were able to recruit very few patients, increased the size of clusters
and increased the survival rate for the trial population by omitting patients who could not be reached
quickly and had a very low chance of survival. These considerations should all have helped to improve
power to detect a difference between the LUCAS-2 device and manual compression arms in the trial.
Eligibility for individual patients
Patients were eligible if they met all four of the criteria below:
1. Cardiac arrest in the out-of-hospital environment.
2. First ambulance resource was a trial vehicle.
3. Resuscitation attempt was initiated by the attending ambulance clinicians, in accordance with JRCALC
guidelines.53
4. The patient was known, or believed to be, aged ≥ 18 years.
The exclusion criteria were:
l cardiac arrest caused by trauma
l known or clinically apparent pregnancy.
All patients who fulfilled the eligibility criteria were included in the trial. The JRCALC Recognition of Life
Extinction (ROLE) guidelines53 were applied to determine patients for whom a resuscitation attempt was
inappropriate. This is the case when there is no chance of survival; when the resuscitation attempt would
be futile and distressing for relatives, friends and health-care personnel; and when time and resources
would be wasted undertaking such measures. If there was clear evidence that life was extinct (Box 1) or if
the patient had a ‘do not attempt resuscitation’ order, ambulance staff were authorised to recognise death
and withhold CPR.
The LUCAS-2 device cannot be used if patients are too large or too small: the device fits patients with a
sternum height of 17.0–30.3 cm and a chest width of < 45 cm. However, patient size was not an exclusion
criterion because it would be impossible to apply correctly to the manual compression group, hence
potentially introducing bias. Moreover, it was appropriate to include the small proportion of patients who
were too large or too small for the LUCAS-2 device in the trial, in accordance with intention-to-treat (ITT)
principles. The trial estimated the impact of the LUCAS-2 device on the survival rate among the whole
cardiac arrest population. In one Swedish study,29 only 3 out of 159 patients (1.9%) were found to be
too small or too large for the LUCAS device. We therefore anticipated that there would be only a small
number of patients for whom the LUCAS-2 device could not be used, especially as the LUCAS-2 device
accommodates larger patients than the LUCAS version 1 device that was used in the Swedish study.
Randomisation
Randomisation of trial vehicles to the LUCAS-2 and control arms was performed by the study statisticians
before the devices were supplied to participating stations. As the number of LUCAS-2 devices was limited,
it was inefficient to randomise vehicles in a 1 : 1 ratio. This would have entailed some vehicles at each station
not contributing to the trial and, hence, non-inclusion of potentially eligible cardiac arrest patients. It would
also be operationally more difficult for ambulance service staff, as procedures would be different between
trial and non-trial vehicles. Because there was little cost associated with including additional standard care
clusters, we included all eligible vehicles at each station in the trial, with the majority allocated to the control
arm and a random selection (stratified by type of vehicle) allocated to the LUCAS-2 arm. This ensured that all
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eligible cardiac arrests were included in the trial. The number of LUCAS-2 devices allocated to each station
was determined by the number of vehicles. In all of the stations, at least one device was allocated to a rapid
response vehicle (RRV) and one to an ambulance (unless there were no vehicles of a type at a station). The
number of vehicles available varied and it was not possible to ensure that allocation was in any precise ratio,
but we aimed for the ratio of LUCAS-2 to standard care vehicles to be approximately 1 : 2. If new vehicles
were brought into service at participating stations during the recruitment period, these were also randomised.
The randomisation sequence was computer generated, with stratification by station and type of vehicle.
Once randomised, a vehicle’s allocation could not be changed and it remained in that group throughout
the trial. Clusters were terminated if a vehicle left the trial permanently (e.g. was scrapped or withdrawn
from front-line service).
BOX 1 The ROLE criteria
Massive cranial and cerebral destruction.
Hemicorporectomy.
Massive truncal injury incompatible with life (including decapitation).
Decomposition/putrefaction.
Incineration.
Hypostasis.
Rigor mortis.
A valid ‘do not attempt resuscitation’ order or an advanced directive (living will) that states the wish of the
patient not to undergo attempted resuscitation.
When the patient’s death is expected as a result of terminal illness.
Efforts would be futile, as defined by the combination of all three of the following being present:
1. more than 15 minutes since the onset of collapse.
2. no bystander CPR prior to arrival of the ambulance.
3. asystole (flat line) for > 30 seconds on the ECG monitor screen.
Exceptions are:
1. drowning
2. drug overdose/poisoning
3. trauma
4. submersion of adults for longer than 1 hour.
ECG, electrocardiography.
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Early in the trial it became apparent that ambulances and RRVs frequently moved between stations, and it
was not possible to identify a set of vehicles that would be consistently present at a participating station.
Hence, many of the vehicles initially randomised at a station moved elsewhere and were replaced by vehicles
that had not been randomised. This resulted in a low proportion of potentially eligible cardiac arrests being
attended by trial vehicles. We therefore tried as far as possible to randomise stations that were geographically
close, so that most transfers of vehicles between stations would be to another station that was participating in
the trial. This reduced the proportion of cardiac arrests that were attended by non-trial vehicles.
A slightly different method of randomisation was used by the North East Ambulance Service. This region used
a different system of allocation of vehicles, in which vehicles did not have a base station, but were based at
two main depots. From here, vehicles were allocated to stations as needed. This meant that there was a
major problem with vehicle rotations; vehicles rarely stayed at the same station for a prolonged period, and
there were no geographically close sets of stations around which vehicles tended to rotate. Because it was
possible (for logistical reasons) to include only a limited number of stations in this region in the trial, the
investigators and Trial Steering Committee (TSC) felt that it was appropriate to use a different system of
randomisation for this region. This was intended to be equivalent to the usual system of randomisation by
vehicle. The North East Ambulance Service randomisation system used ‘virtual vehicles’; at each station, each
vehicle place was randomised to the LUCAS-2 or control arm, with stratification by type of vehicle. So, for
example, if there were three ambulances at a station, number two might be randomised to the LUCAS-2 arm,
so whichever ambulance filled that position on a particular day would carry the LUCAS-2 device and recruit
patients to the LUCAS-2 arm. The disadvantage of this system was that the LUCAS-2 devices did not stay with
the same vehicle, but had to be loaded on to the correct vehicle at the beginning of each shift and removed
afterwards. However, the crews had done this for a previous trial, so were used to the process, and no
problems of missing LUCAS-2 devices were encountered. This system ensured that cardiac arrests attended by
ambulances from participating stations would be recruited to the trial. If we had used the same system in the
North East Ambulance Service as elsewhere, then the recruitment rate would have been much lower.
Treatment allocation
A dispatch centre in each region co-ordinated the emergency response. The nearest available RRV or
ambulance was dispatched to cases of suspected cardiac arrest. Back-up was provided by a second vehicle
as soon as possible.
Treatment allocation of each individual participant was determined by the first trial vehicle to arrive on
scene. If this was a LUCAS-2 device-containing vehicle, the patient was assigned to the LUCAS-2 arm, and
if it was a non-LUCAS-2 device-containing vehicle (control), the patient was allocated to the manual
compression arm. If the trial vehicle was not the first ambulance service vehicle to arrive on scene – that is,
a double-manned ambulance or a single-manned RRV that was not part of the trial had already arrived
and commenced resuscitation – the patient was not included in the trial. If the first response on scene was
a community responder (volunteer members of the public trained in basic life support and defibrillation,
despatched by ambulance control) or other responses (such as motorbike, helicopter or unmarked car)
then the patient was included and their allocation was determined by the first trial vehicle to arrive,
providing that continued resuscitation was indicated.
We aimed to include all eligible patients who were attended by a participating vehicle during the trial
recruitment period. The attending ambulance clinicians determined whether or not a resuscitation attempt
was appropriate, according to the JRCALC guidelines.53 Patients were regarded as participating in the trial
when a resuscitation attempt was initiated by the attending ambulance service personnel.
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Consent
Ethical considerations
The occurrence of a cardiac arrest out of hospital is unpredictable. Within seconds of cardiac arrest, a
person becomes unconscious and thus incapacitated. It was not therefore possible to obtain prospective
consent directly from the research participant.
Treatment (in the form of CPR) must be started immediately in an attempt to save the person’s life. In this
setting it was not practical to consult a carer or independent registered medical practitioner without
placing the potential participant at risk of harm from delaying treatment.
Conducting research in emergency situations in which a patient lacks capacity is regulated by the Mental
Capacity Act (2005)54 for England and Wales. The PARAMEDIC trial was approved in accordance with
these requirements by the Coventry Research Ethics Committee (REC) (reference number 09/H1210/69).
Ethics approval was also gained from the Scotland A REC, but the Scottish Ambulance Service
subsequently withdrew from the study.
Approaching survivors
The nature of the condition meant that the majority (85–90%) of people in the study would not survive.
Of those patients admitted to hospital alive, the majority (approximately 80%) would be comatose and
admitted to an ICU (and thus remain incapacitated). Following admission to intensive care, approximately
half of the people who initially survive die without regaining capacity (on average within 48 hours). The
average duration of hospital stay for survivors is 18 days.55
To avoid unnecessary distress to the relatives of the deceased, the timing of the approach was important
and had to balance the need to inform at an early opportunity while determining – as accurately as
possible – which patients had died. Pilot work for this trial established that it is not possible for ambulance
services to determine with sufficient accuracy which patients have died, so the procedure was revised,
based on the procedures of the ICON (Intensive Care Outcome Network) study.56
The participating ambulance services conducted their own checks on patients’ survival using existing data
systems, which differed between services. Where possible, ambulance services consulted the NHS Patient
Demographics Service. Other checks carried out by either the ambulance service and/or the Warwick
Clinical Trials Unit (WCTU), included contacts with hospitals, general practitioners (GPs), the Intensive Care
National Audit and Research Centre (ICNARC) and local registrars of births and deaths (see Identification of
cardiac arrests).
If a patient was transported to hospital, his/her clinical and contact details were sent to the study
co-ordinating centre at the WCTU. Staff at the co-ordinating centre checked the status of each potential
survivor with the Medical Research Information Service (MRIS) approximately 6 weeks after the patient’s
cardiac arrest. This timing of the approach was selected to ensure that the majority of deaths had been
included in the MRIS database. All of the survivors were flagged on the MRIS database and the trial
co-ordinating centre was informed of any subsequent deaths.
After these checks, if someone was still believed to be alive then the co-ordinating centre contacted the
person at his/her home address by letter to provide information about the study and the follow-up. If there
was no response after 2 weeks, then the co-ordinating centre tried to contact the patient by telephone
(if the telephone number was known) or by letter. If the patient wished to take part in the follow-up, then
they could contact the WCTU by using the reply slip, telephone or e-mail. This gave the participants an
opportunity to discuss the study and, if they were happy to proceed, a 3-month follow-up appointment
was made. The consent form was either returned by post or signed at the 3-month follow-up visit. Patients
who did not respond were approached again at 10 months post cardiac arrest in an attempt to invite
them to participate in a 12-month visit.
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In the event that the co-ordinating centre was notified (or had reason to believe) that a patient lacked
capacity, an approach was made to his/her GP in order to establish if the patient had capacity to consent.
In the event that a patient lacked capacity to consent, we sought the views of a personal consultee in order
to establish the patient’s wishes. If a personal consultee could not be identified, a carer (unconnected with
the study) determined if the patient would be likely to consent to follow-up.
Protection against bias
Cluster design
One of the major potential sources of bias in cluster randomised trials is selection bias, which can arise if
different patients are selected for inclusion in the two trial arms. This can arise when clinicians or people
selecting patients are aware of the allocation of the cluster and they may consciously or unconsciously
apply inclusion criteria differently depending on the randomised intervention. There is greater scope for
selection bias if a large proportion of potentially eligible patients are not included in the trial. In this trial,
paramedics assessing patients for inclusion were aware of the allocations; however, we aimed to identify
and include close to 100% of the eligible patients, using a combination of methods for identifying eligible
patients (see Eligibility for individual patients). This should avoid most selection bias.
Threshold for resuscitation
As the ambulance clinicians who were delivering the interventions were not blinded, there was a possibility
that bias could be introduced by different thresholds for resuscitation between the LUCAS-2 and standard
care arms: if they believed strongly that the LUCAS-2 device was effective, some of them might have
attempted resuscitation in the LUCAS-2 arm on patients who had no chance of survival, and for whom a
resuscitation attempt was therefore inappropriate. This would have resulted in a group of patients with a
very low probability of survival being recruited to the LUCAS-2 arm but not to the standard care arm,
potentially masking any beneficial effect of the LUCAS-2 device. We used several strategies to prevent this
bias from occurring, to detect if it was to happen and to correct it if necessary.
First, the criteria that were used to determine whether or not a resuscitation attempt was appropriate, and
hence whether or not the patient was eligible, were as objective as possible. The JRCALC ROLE criteria53
were used by all of the participating ambulance services to determine when a resuscitation attempt is
inappropriate, and this continued in the trial (see Eligibility for individual patients). Ambulance clinicians
were therefore familiar with the application of these criteria and no change of practice was needed during
the trial. However, there remained scope for differential application of the criteria to the two trial arms,
so further strategies were devised.
Second, all ambulance clinicians in the trial were trained in the trial procedures57 to ensure that they
understood the rationale for the trial and the importance of following the trial procedures. The training
included a review of existing evidence so that participating ambulance clinicians understood the current
position of equipoise regarding the effectiveness of the LUCAS-2 device and discussion of potential sources
of bias in the trial and the importance of applying the inclusion/exclusion criteria rigorously to both arms.
Training continued throughout the recruitment period to ensure that any new staff were trained before
recruiting and that important messages were continually and correctly reinforced (see Appendix 2).
Third, we instituted a programme of regular monitoring of the characteristics of patients who were
recruited to the two trial arms, the number of cardiac arrests in each arm when no resuscitation attempt
was made and the proportion of cardiac arrests included in the trial in order to detect any imbalances
that may be caused by different thresholds for resuscitation. We also monitored the presenting rhythm,
proportion of witnessed and unwitnessed arrests, presence of bystander CPR and time from ‘999’ call to
crew arrival (using ambulance computer log data). If a lower threshold for attempting resuscitation in the
LUCAS-2 arm existed, then we would find a greater number of recruits and a greater proportion of cardiac
arrests with resuscitation attempts, a greater proportion with unfavourable presenting rhythms, a lower
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proportion of witnessed arrests and with bystander CPR and longer times from ‘999’ call to start of
resuscitation in the LUCAS-2 group.
Finally, if necessary, we corrected for any inclusion bias in the statistical analysis of the trial, by adjustment
of the analysis to take account of imbalance in factors such as presenting rhythm, time since ‘999’ call and
presence of bystander CPR. We expected any potential inclusion bias to affect only the group of patients
who were least likely to survive and that it would not affect patients in whom a resuscitation attempt
would always be made (e.g. those with presenting rhythms with the highest probability of survival) and
therefore a comparison between the LUCAS-2 device and manual compression in the subgroups of
patients in whom resuscitation was known to be appropriate would be unaffected.
Monitoring device usage
The LUCAS-2 devices continuously record data when switched on. Data on the date, time and duration of
use are stored in the device’s internal memory and can be downloaded when the device is serviced. We
intended to use these data to verify whether or not the LUCAS-2 device was used for all cardiac arrests in
the LUCAS-2 group or any in the control group. However, in practice, obtaining access to the data was
difficult, as they can be accessed only by the manufacturers at the time of device servicing and special
software is required to interpret the data. Data were extracted from the devices during recruitment, and
supplied to the trial team, but, through efforts to match up LUCAS-2 device usage with dates and times of
resuscitations of recruited patients, it became apparent that it was possible to verify LUCAS-2 device use
during resuscitation for only a small number of patients. The main reasons for this were, first, the lack of
LUCAS-2 device clock synchronisation with the Universal Time clock; second, the difficulty of identifying
the dates and times of LUCAS-2 device use for a resuscitation attempt, as opposed to device testing,
demonstration or training; and, third, the lack of correspondence between the times of use recorded by the
devices and those of recruitments recorded by ambulance services. Efforts to verify LUCAS-2 device use for
resuscitation attempts based on the data recorded by the devices were discontinued.
Compliance was monitored by the direct report of ambulance service personnel on the patient report form
(PRF). For each cardiac arrest, ambulance clinicians were asked to report whether or not the LUCAS-2
device had been used, and instances of non-compliance were followed up with the crews involved by the
paramedic research fellows.
Monitoring quality of cardiopulmonary resuscitation
For interpretation of the trial’s results, it is helpful to understand the quality of CPR provided as standard
care during the trial, as this may help to explain the observed differences. For example, if the CPR quality
in the control group was extremely high, it would make it less likely that a treatment benefit would be
seen in the LUCAS-2 group.
We originally planned to monitor CPR quality using data recorded by defibrillators during resuscitation
attempts, from which we would calculate the compression fraction, that is, the percentage of time in which
chest compressions are carried out (to ascertain pauses in the chest compressions). This would provide a
measure of CPR quality in the control group and would allow verification of LUCAS-2 device use in the
LUCAS-2 group. However, direct measurement of the quality of CPR in trial patients proved unachievable,
for several reasons. First, different defibrillators were in use in the four ambulance services, which required
different approaches to extract data. In two services, memory cards were required. These needed to be
inserted before use, then removed and data extracted before the next use. This was operationally impractical.
In the remaining two ambulance services, data were stored in the defibrillators, but extraction and analysis of
them were challenging, and it proved to be extremely difficult to download the data reliably after resuscitation
attempts. We were therefore forced to abandon attempts to collect data on CPR quality from trial patients.
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Instead, we performed a study to estimate the ‘background’ CPR quality in each ambulance service.
Approximately 20% of staff working in the trial areas were invited to take part in an evaluation of the
quality of simulated CPR (using a manikin). Between February 2013 and June 2013 each staff member was
asked to demonstrate ALS of an adult patient in VF, as they would do normally in the field. Data were
recorded for around 5 minutes. The staff were able to work solo or as a double-person crew, whichever
was their usual practice. We recorded compression depth, compression rate and compression fraction.
Data were recorded anonymously and were not related back to staff performance.
Blinding
Because of the nature of the interventions, ambulance clinicians could not be blinded and were aware of
treatment allocations. Control room personnel were blinded to the allocation of the ambulance service
vehicles, to ensure that there was no bias in whether a LUCAS-2 device-containing or control vehicle was
sent to an incident that was likely to be a cardiac arrest. Normally, the closest vehicle would be sent, which
would not favour either LUCAS-2 or control arms of the trial. Ambulance service clinical staff were not
blinded; vehicles randomly assigned to the LUCAS-2 arm were identified to them at the start of the shift
during vehicle checks and through stickers in the cab and outside the vehicle.
Patients themselves were unconscious and therefore unaware of their treatment allocation at the time of
the intervention, although 19 patients may have been subsequently unblinded by relatives or friends who
were aware that the LUCAS-2 device was used. We sought to ensure blinding of outcome assessment
as far as possible. Research nurses/paramedics assessing outcomes at 3 and 12 months’ follow-up were
blinded to treatment group and endeavoured to maintain their blinding during the follow-up assessments.
Mortality is an objective outcome, and its assessment was very unlikely to be influenced by knowledge of
the treatment allocation.
Training
Paramedics seconded to work on the trial, along with clinical educator staff, trained all of the operational
ambulance staff to use the LUCAS-2 device. Because of vehicle movements and staff rotations, staff-serviced
vehicles were randomly assigned to both LUCAS-2 and manual groups; hence, all staff would potentially
treat patients in the intervention arm. Training was carefully designed by the ambulance services on the basis
of the manufacturer’s guidance. Because of the pragmatic design of this trial, training was developed in
accordance with the process by which new technology would be introduced in routine practice into NHS
ambulance services. This preparation included access to online training resources56 and included 1–2 hours of
face-to-face training, updated annually. Training covered the study protocol and procedures, how to operate
the LUCAS-2 device and the importance of high-quality CPR. Training included hands-on device deployment
practice with a resuscitation manikin and emphasised the importance of rapid deployment with minimum
interruptions in CPR. A competency checklist was completed before authorising staff to deploy the LUCAS-2
device correctly (see Appendix 2). Research paramedics reviewed all cases and provided feedback to
individual staff as required. The rate of device use and reasons for non-use were fed back to participating
services on a quarterly basis.
Clinical management of patients in the trial
The clinical management of patients in the trial was undertaken in accordance with the details given in the
trial protocol.
The CPR that was delivered to all of the patients followed the International Liaison Committee for
Resuscitation, European Resuscitation Council and Resuscitation Council (UK) guidelines that were in force
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during the study period. These guidelines are adopted for ambulance use by the JRCALC and the JRCALC’s
guidelines for clinical practice form the basis for all of the resuscitation attempts that are delivered by
ambulance crews.53 At the commencement of the trial, the 2005 resuscitation guidelines were in place,
but new resuscitation guidelines were published on 18 October 201058 and incorporated by all ambulance
trusts that were involved in the trial during the following 12 months. All standard ALS interventions were
provided, including drug administration, defibrillation and advanced airway management as required.
In both arms, if the patient did not respond despite full ALS intervention and remained asystolic for
> 20 minutes, the resuscitation attempt could be discontinued. Unless these criteria were met, resuscitation
was continued and the patient was transported to the nearest emergency department with ongoing CPR.
Intervention arm
The LUCAS-2 device used in the trial was the latest version of the LUCAS-2 device, manufactured by Jolife
AB and distributed by Physio-Control UK, Watford, UK.
Patients who were allocated to the intervention arm (LUCAS-2 device) received mechanical chest
compressions in place of standard manual chest compressions.
On arrival, after confirming cardiac arrest, manual CPR was commenced while the LUCAS-2 device was
prepared and applied. Following this, the initial cardiac rhythm was assessed. If the patient was in VF or VT
then a countershock was administered in accordance with JRCALC/ALS guidelines. Operational experience
showed that the LUCAS-2 device could be deployed within 20–30 seconds of arrival at the patient’s
location. Prior to intubation, compressions were provided using the 30 compressions/two ventilations
mode. If the patient was intubated, asynchronous compressions and ventilations were provided, with a
ventilation rate of 10 per minute.
Defibrillation was performed using the following sequence: pause LUCAS-2 device, analyse heart rhythm;
if shock indicated, restart LUCAS-2 device, charge, deliver shock and continue CPR for 2 minutes. This
minimised deleterious pre- and post-shock pauses in compressions. The LUCAS-2 device was used in place
of standard chest compressions as long as continued resuscitation was indicated, including resuscitation in
the field and during transport to hospital.
The trial intervention ceased after care was handed over to the medical team in the hospital or the patient
was declared deceased according to the ROLE criteria.53
Manual chest compression arm
On arrival, after confirming cardiac arrest, manual CPR was commenced and the initial cardiac rhythm was
assessed. If the patient was in VF or pulseless VT, then a countershock was applied. Prior to intubation,
compressions were provided using the 30 compressions/two ventilations mode. If the patient was intubated,
asynchronous compressions and ventilations were provided, with a ventilation rate of 10 per minute.
Minimising interruptions in chest compressions is critical for optimising the chances that a shock is
successful. However, it is currently considered unsafe to perform defibrillation during manual chest
compression. Defibrillation was therefore performed using current UK recommendations, which are as
follows: stop CPR; analyse heart rhythm, charge defibrillator, deliver shock, restart chest compressions and
continue CPR for 2 minutes.
Serious adverse event reporting
Definitions
Adverse events
An adverse event (AE) is ‘Any untoward medical occurrence in a patient or clinical investigation participant
taking part in health-care research, which does not necessarily have a causal relationship with the research’.59
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Serious adverse events
The definition of a serious adverse event (SAE) is an untoward and unexpected occurrence that:
l results in death
l is immediately life-threatening
l requires hospitalisation or prolongation of existing hospitalisation
l results in persistent or significant disability, or incapacity
l consists of a congenital anomaly or birth defect (not relevant to this trial population).59
Additional terms for device trials
For trials of devices, additional terms are used and are defined as follows.
Adverse device effect/event
Any unfavourable or unintended response to a medical device.
Serious adverse device effect/event
A serious adverse device effect/event (SADE) is an adverse device effect/event (ADE) that has resulted in
any of the consequences of a SAE or might have led to those consequences if suitable action/intervention
had not been taken.
Incident
Any malfunction or deterioration in the characteristics and/or performance of a device, as well as any
inadequacy in the labelling or instructions for use, which, directly or indirectly, might lead or might have led,
to the death of a patient or user, or other persons or to the serious deterioration in their state of health.59
Events that should be reported
All AEs and SADEs and incidents were reported to the trial co-ordinating centre on the appropriate forms
(see Appendix 3).
All of the patients in this trial were in an immediately life-threatening situation; many would not survive
and all of those who did were hospitalised. These situations were, therefore, expected, and events leading
to any of them were reported as SAE/SADEs only if their cause was clearly separate from the cardiac arrest.
Events that were related to cardiac arrest and would be expected in patients undergoing attempted
resuscitation (including death and hospitalisation) were not reported.
Therefore, events were reported as SAE/SADEs if they were:
l serious
l and were potentially related to trial participation (i.e. they may have resulted from study treatment such
as use of the LUCAS-2 device)
l and were unexpected (i.e. that the event was not an expected occurrence for patients who have had a
cardiac arrest).
Examples of events that may be SAE/SADEs were the use of the LUCAS-2 device causing a new injury that
endangered the patient, malfunction of the device causing injury to ambulance clinicians and malfunction
of the device leading to inadequate chest compression.
Reporting serious adverse events
Events satisfying the criteria given above were reported to the study co-ordinating centre, using the event
report form, as soon as they became apparent (see Appendix 3).
The SAE/SADE reports that were received by the co-ordinating centre were reviewed on receipt by the
chief investigators, and those that were considered to satisfy the criteria for being related to the device
and unexpected were notified to the main REC, the Medicines and Healthcare products Regulation Agency
(MHRA) and manufacturer within 15 days of receipt.
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The SAE reports were also reviewed by the Data Monitoring Committee (DMC) at its regular meetings.
AEs that were not considered to be serious were logged and included in annual progress reports.
Data collection
Identification of cardiac arrests
Data were recorded on all of the cardiac arrests within the trial areas. This allowed assessment of the
proportion of cardiac arrests that were enrolled into the trial and helped to ensure that no eligible cardiac
arrests were missed. Data were collected by the attending ambulance clinicians, using the routinely
completed PRF. Data from the PRFs were then transcribed on to the trial case report forms (CRFs) by the
trial research fellows (see Appendix 4). The data collection was retrospective and each ambulance service
had its own system, which meant that identifying cardiac arrest cases was challenging. The ambulance
services, generally, had more than one system for identifying cardiac arrest cases to ensure that none was
missed. One ambulance service had to go through all daily paper PRFs on station; others had electronic
PRFs and were able to perform searches through a database. Other methods included linking in with
national reporting of cardiac arrests to the Department of Health.
Data forms were collected in a central place at participating ambulance stations and collected by research
paramedics on a weekly basis. For ineligible cardiac arrests (no resuscitation attempt, aged < 18 years,
pregnant, traumatic aetiology, non-trial vehicle was first on scene), the ambulance service also sent the
trial co-ordinating centre details of the arrests for monitoring purposes.
Hospitals did not undertake prospective data collection for trial participants because of the logistical
difficulties that this would present. Hospitals were contacted, as necessary, to seek information about
whether patients had been discharged or had died in hospital before contacting them for follow-up.
Further details about length of stay in the ICU and hospital were also sought from hospitals, ICNARC and
Hospital Episode Statistics (HES). Authority was granted by the Confidentiality Advisory Group to collect
these data without seeking consent from the next of kin.
Deaths
Before admission
Deaths before admission to hospital were recorded by ambulance services and data for these patients
were supplied to the trial database in anonymised form, as no personal identifiers were needed for
follow-up. If a patient was transported to hospital, before transfer of identifiable data to the study
co-ordinating centre, ambulance services conducted their own checks for survival. When access was
granted locally, research fellows were able to search NHS Summary Care Records. They would also check
with hospitals, where relevant.
To identify later deaths, all of the potential survivors had their status checked with MRIS approximately
6 weeks after their cardiac arrest. Therefore, the majority of deaths should have been included in the MRIS
database. Deaths are normally included within 4 weeks of issue of a death certificate and we anticipated
that the majority of certificates would be issued within a few days. All survivors were flagged on the
MRIS database to ensure that the study was notified immediately if their death was registered. Issue of a
death certificate may be delayed in some cases by referral to a coroner, but, in most cases, the coroner’s
investigation will be concluded quickly and the delay to inclusion of the death on the MRIS database will
be small. In addition, before writing to patients we also contacted their GP (if known) to check on survival.
At follow-up
Survivors were followed up approximately 90 days after their cardiac arrest, by a home visit or telephone
contact from a study research nurse/paramedic. At this visit quality-of-life tools (SF-1243 and EQ-5D44) and
an assessment of CPC score were completed.
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If a patient was believed to be alive but had not responded to the invitation to take part in the follow-up
or did not want to take part, we approached his/her GP, hospital or ambulance service for any repeat visits
for information on the patient’s CPC score.
The second follow-up visit at 12 months included measurement of quality of life (SF-1241 and EQ-5D42),
anxiety and depression (HADS47), post-traumatic stress (PCL-C48) and cognitive outcome (MMSE46). The
NHS Demographics Batch Service was used to identify participants who had changed address since the last
contact. Health service and social care resource use was reported in a patient self-completed questionnaire
that was provided to participants at the 3- and 12-month follow-up visits (see Appendix 5).
Data management
All of the data collected during the trial were handled and stored in accordance with the Data Protection Act
1998.60 Data were, as far as possible, anonymised, but this trial involved the use of identifiable personal data
for follow-up. All transfer of data between ambulance services and the study co-ordinating centre used
secure methods, such as encrypted e-mail. All of the study data were entered into a study-specific database,
which was set up by the programming team at the WCTU at the start of the study. All specifications (i.e.
database variables, validation checks, screens) were agreed between the programmer, statistician, chief
investigators and trial co-ordinator. All trial documentation and data were archived after completion of the
trial and are stored in accordance with the WCTU standard operating procedures61 (see Appendix 7).
Statistical methods
Power and sample size
Incidence of primary outcome
At the time of initiation of this trial, there were few data on the incidence of survival after cardiac arrest, and
most of these referred to survival to hospital discharge rather than survival to 30 days. However, as most
mortality will occur in the first days after cardiac arrest, we expected survival to hospital discharge and to
30 days to be similar. A systematic review, published in 2005,62 has summarised all European data. The overall
incidence of survival to hospital discharge was 10.7%, with 21.2% survival to discharge for patients with an
initial rhythm of VF. This review62 included eight studies from the UK, in which the mean survival to hospital
discharge was 8.1% overall and 17.7% for patients with initial VF rhythm. Data on survival to discharge from
audits of UK ambulance services were limited, because at the time of the study few ambulance services
collected outcome data for patients beyond admission to hospital. Figures from the London Ambulance
Service (2006–7) indicated a survival rate to discharge of 5.2% (95% CI 4.4% to 6.0%).63 National audit data
for England (2006) indicate that the proportion of patients for whom resuscitation is attempted (and who
have ROSC at admission to hospital) varied between 10% and 26% for different ambulance services.64 The
overall national figure (2004–6) was 14–16%. Estimates of mortality in hospital vary from 50% to 70%;
hence, the incidence of survival to discharge is expected to be between 4.5% and 8%.65 A reasonable
conservative estimate of survival to 30 days is 5% and we have used this value in the sample size calculations.
Intracluster correlation coefficient
No data currently exist from which a relevant intracluster correlation coefficient (ICC) for this trial can be
calculated. We have therefore assumed a conservative value of 0.01 for the sample size calculation. We
expected that, because the LUCAS-2 device and manual compression clusters recruited from the same
geographical areas and hence the same populations, the ICC would be low. The value of the ICC was
monitored at the interim analyses by the DMC.
Cluster size
Predicting the expected cluster size during the trial was difficult because of expected changes in the
vehicles in service and the proportion of eligible cardiac arrests that they were likely to attend. Moreover,
there was likely to be considerable variation in the number of cardiac arrests attended by each vehicle
(i.e. variation in cluster size). Data from the West Midlands Ambulance Service suggested that each vehicle
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would attend around 10–20 cardiac arrests per year; allowing for non-resuscitations and periods off the
road, a reasonable estimate of the cluster size over a 2-year recruitment period was 15.
The sample size was revised during recruitment in response to information that some of the parameters
differed from the assumptions that were made at the start of the trial. The original sample size calculation
is given, followed by the revised version.
Original sample size
The required sample size is sensitive to variation in several parameters that were not precisely known at the
start of the trial, including the incidence of the primary outcome in the manual compression group and the
ICC. We aimed to be able to detect, with 80% power, an increase in the incidence of survival to 30 days
from 5% in the manual compression group to 7.5% in the LUCAS-2 group [a risk ratio (RR) of 1.5]. An
increase in survival from 5% to 7.5% corresponds with a number needed to treat of 40 – or one extra life
saved per 40 resuscitation attempts. This would translate into around 625 lives saved per year in the UK. In
an individually randomised trial this would require 2942 participants. Allowing for clustering, assuming an
ICC of 0.01 and a cluster size of 15, this would require 224 clusters if using a 1 : 1 randomisation ratio
(112 LUCAS-2 group, 112 manual group; 3360 participants in total).
Because the number of LUCAS-2 devices that were available to the trial was limited, it was more efficient
not to use a fixed 1 : 1 randomisation ratio (see Randomisations), but to randomise a number of LUCAS-2
devices among all of the vehicles at each ambulance station. This allowed inclusion in the trial of all cardiac
arrests attended by vehicles from that station. The numbers of clusters required for 80% power to detect
the difference specified above, with different randomisation ratios and cluster sizes, is shown in Table 1.
Our target was to randomise 82 LUCAS-2 clusters and 163 standard care clusters and a total sample size of
3675 participants. We expected to determine the primary outcome for close to 100% of trial participants,
so no inflation of the sample size to allow for losses to follow-up of individual participants was proposed.
With this sample size, the 95% CI around an estimated treatment effect of a RR of 1.50 would be 1.14 to
1.94, including adjustment for clustering.
Within this sample size we expected around 25% of patients to have an initial rhythm of VF (approximately
920 patients). This subgroup was expected to have significantly higher survival than the rest of the
TABLE 1 Number of clusters required for 80% power to detect an increase in the incidence of survival to 30 days in
the manual compression and LUCAS-2 groups
Cluster size Control
Clusters required
Total number of participantsTotal LUCAS-2 Control
14 1 : 1 238 119 119 3332
1 : 2 260 87 173 3640
15 1 : 1 224 112 112 3360
1 : 2 245 82 163 3675
16 1 : 1 212 106 106 3392
1 : 2 231 77 154 3696
18 1 : 1 192 96 96 3456
1 : 2 210 70 140 3780
20 1 : 1 176 88 88 3520
1 : 2 192 64 128 3840
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population, of around 15%. The number in this subgroup was sufficient to show an increase from 15% to
22.8% (RR 1.52) with 80% power, allowing for clustering.
The DMC monitored the values of all of the parameters of the sample size calculation at interim analyses
and advised on any necessary modifications to the sample size.
Revision to sample size
The target sample size was reviewed in September 2012, after recruitment of 2469 patients, in response
to an observed high level of non-compliance in the LUCAS-2 arm and to incorporate updated figures for
the expected cluster size, ICC and ratio of control to LUCAS-2 clusters. The sample size re-estimation did
not use any information from comparisons between the trial groups.
Because non-compliance would reduce the difference between the groups and potentially obscure a
treatment effect due to the LUCAS-2 device, we used complier average causal effect (CACE) analysis66,67 as
well as ITT analysis. This approach estimates the unadjusted odds ratio (OR) for the treatment effect among
compliers, without introducing bias by ignoring the random assignment to groups. For re-estimating the
sample size, we defined compliance in the LUCAS-2 group as use of the device, or non-use for legitimate
reasons that would preclude its use in normal clinical practice (such as patients in whom the LUCAS-2
device was contraindicated or if space restriction meant that the LUCAS-2 device could not be deployed).
Using this definition, we estimated that compliance would be around 70% at the end of the trial.
The expected average cluster size was calculated to be approximately nine and the control-to-LUCAS-2
ratio was 1.5 : 1. It was not possible to calculate an ICC from the interim trial data, but it was expected to
be low and a lower value than was assumed in the original calculation (0.001 rather than 0.01) was used.
Using these figures, a sample size of 4344 would maintain the original power of the trial to detect an increase
in survival from 5% to 7.5%, using CACE analysis rather than ITT analysis. The change to the sample size was
approved by the DMC and TSC and the revised target of 4344 was adopted in December 2012.
Statistical analysis
We performed ITT analyses to estimate the treatment effect of the LUCAS-2 device and presented results
as a point estimate (RR or mean difference), with uncertainty estimated by the 95% CI.
We also used CACE analyses to estimate the effect in cardiac arrests when the protocol was followed.66
CACE estimates the treatment effect in people who were randomly assigned to the intervention and who
actually received it, by comparing compliers in the intervention group with those participants in the control
group who would have been compliers if they had been allocated to the intervention group. This analysis
retains the advantages of randomisation and avoids introducing bias, hence CACE is preferred to per-protocol
analysis.67 CACE assumes that the probability of non-compliance with the LUCAS-2 device would be the
same for people who were actually randomised to the control as for those who were randomised to the
LUCAS-2 arm. If allocation is random, this assumption will hold. A second assumption is that outcomes are
not affected just by being randomised to the LUCAS-2 or control groups; in other words, there is no
systematic difference in outcomes between patients attended by LUCAS-2 device-containing vehicles and
those attended by control vehicles, except that caused by the different treatments provided. CACE analysis
enables us to estimate the unobserved proportion of the control group who would have been non-compliers
if randomised to the LUCAS-2 group. We did two CACE analyses, defining compliers in different ways. In
CACE 1, we treated as non-compliant those cases in which the LUCAS-2 device was not used for unknown
or trial-related reasons that would not occur in real-life clinical practice (e.g. crew was not trained in trial
procedures, crew misunderstood the trial protocol, the device was missing from the vehicle). This analysis
omits trial-related non-use and should be a better estimate of the treatment effect in real-world clinical
practice than an ITT analysis. In the CACE 2 analysis, we treated as compliant only those cases in which the
LUCAS-2 device was actually used and this analysis therefore estimates efficacy, that is, the treatment effect
in patients who received LUCAS-2 device treatment.
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For ITT analyses, we used logistic regression models to obtain unadjusted and adjusted ORs and 95% CIs. The
prespecified covariates used in the adjusted models were age, sex, response time, bystander CPR and initial
rhythm. We attempted adjusting for the clustering design using multilevel logistic models using the Statistical
Analysis Software (SAS) GLIMMIX procedure with logit link function based on the binomial distribution.
Because of the extremely low survival rates in each cluster (vehicle), the multilevel models could not be fitted
with the vehicle random effect, as this effect was not estimable. As a result, ordinary logistic regressions were
fitted. We also undertook prespecified subgroup analyses by (1) initial rhythm (shockable vs. non-shockable);
(2) cardiac arrest witnessed versus not witnessed; (3) type of vehicle (RRV vs. ambulance); (4) bystander CPR
versus no bystander CPR; (5) region; (6) aetiology (presumed cardiac or non-cardiac); (7) age; and (8) response
time. The analyses by region and type of vehicle were added during recruitment on the recommendation of the
TSC. We fitted logistic regression models for the primary outcome measure with the inclusion of an interaction
term to examine whether or not the treatment effect differed between the subgroups. Age and response times
are continuous variables and we assessed these using multivariate fractional polynomials68 (see Appendix 8).
We did all analyses using SAS version 9.3 (SAS Institute, Marlow, UK). Interim analyses were conducted at
least once per year during recruitment and supplied confidentially to the DMC. The DMC considered the
results of the interim analysis and made recommendations to the TSC about continuation of recruitment or
any modification to the trial that may have been necessary.
Approvals, registration and governance
The study was approved by the Coventry REC (reference number 09/H1210/69) and sponsored by the
University of Warwick. It was conducted in accordance with the principles of good clinical practice and the
Mental Capacity Act (2005).54,69 The trial was registered on the International Standard Randomised Controlled
Trial Number Register (ISRCTN08233942). Approval was given by the National Information Governance Board
for Health and Social Care Ethics and Confidentiality Committee for access to personal data without consent
(reference number ECC 2–02 (c)/2011). The manufacturers (Jolife AB) and distributors (Physio-Control UK) of
the LUCAS-2 device had no role in the design, conduct, analysis or reporting of the trial. Their role was limited
to supply and servicing of the LUCAS-2 devices and training of study co-ordinating centre personnel.
Several changes to the protocol and procedures were made during the trial (see Table 2). When these
fulfilled the definition of ‘substantial amendments’ according to the UK Clinical Trials regulations, they
were reviewed and approved by the ethics committee.
Staffing
The trial was co-ordinated by a team based at the WCTU. The exact personnel varied during the course of
the trial but included a trial co-ordinator (who had overall management responsibility for the team), trial
administrator, data manager and research nurse (who was responsible for co-ordinating follow-up) (Figure 3).
The statistician, senior project manager and programmer were also based at the WCTU. Each ambulance
service employed a number of research paramedics, who were seconded to the trial for its duration and had
primary responsibility for delivering the trial in their area. They were based with the ambulance services, but
worked closely with the central co-ordinating team. Their role was to deliver training, manage the devices
and organise data collection. Some of the research paramedics additionally performed follow-up visits. These
personnel were key to the successful delivery of the trial. As active paramedics, they had detailed knowledge
of the procedures and challenges of their own ambulance service, and were able to design systems and
procedures that would be successful in their area.
Protocol amendments
There have been 11 substantial and non-substantial amendments to the trial documentation (Table 2).
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(a)
Trial Co-ordinating Unit
(WCTU)
structure
Chief investigators × 2
Senior project manager
Co-investigators
Trial co-ordinatorTrainee trial co-ordinator Recruitment facilitator
Data clerk Trial administrator
Principal investigators × 4
R&D managers × 4
Research fellows × 12
Audit clerks × 2
Ambulance
service structure
(b)
FIGURE 3 Staff organogram. R&D, research and development.
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Chapter 3 Trial results
Overview of recruitment
Recruitment of clusters
Four hundred and eighteen emergency vehicles (287 double-manned ambulances and 131 single-manned
RRVs), at 86 ambulance stations, were included in the trial. One hundred and forty-seven vehicles
(100 ambulances and 47 RRVs) were assigned to the LUCAS-2 group and 271 clusters (187 ambulances
and 84 RRVs) were randomised to the control group (Table 3 and Figure 4). The overall LUCAS-2-to-
control ratio was 1 : 1.8 (1 : 1.87 for ambulances and 1 : 1.79 for RRVs). Seventy-two clusters were
terminated early during the recruitment period, for a variety of reasons, including the vehicle being taken
out of front-line service, scrapped or transferred to a station that was out of the trial area.
TABLE 3 Number of vehicles randomised, by trial arm, in each locality
Locality Number of stations
Number of vehicles
Ambulance RRV
LUCAS-2 Control LUCAS-2 Control
West Midlands
Birmingham 24 27 49 12 24
Black Country 14 12 25 4 9
Coventry & Warwickshire 8 14 27 10 16
South Central
SCAS North 3 9 13 3 8
SCAS South 2 6 18 2 3
North East
Durham 2 1 2 1 1
North Tyne 6 1 5 1 0
South Tyne 7 3 6 2 4
Teesside 1 3 4 1 4
Wales
ABM East 3 4 9 3 3
ABM West 4 5 7 1 4
Cardiff 2 5 8 1 3
Llanelli 1 2 2 2 2
Newport 2 4 6 2 2
Vale of Glamorgan 2 4 6 2 1
Total 100 187 47 84
ABM, Abertawe Bro Morgannwg; SCAS, South Central Ambulance Service.
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Stations were opened for recruitment and vehicles were randomised between April 2010 and February
2013, so the duration of recruitment for each cluster varied between 4 and 38 months. The number of
patients recruited by each vehicle was also very variable, ranging from 0 to 41 patients (Figure 5), with a
mean cluster size of 13 patients in the LUCAS-2 arm and 11 in the control arm. Some of the zeros are
accounted for by five stations with 17 vehicles that never commenced active recruitment. Individual
ambulance staff attended on average 4.1 eligible cardiac arrests [standard deviation (SD) 3.6 eligible
cardiac arrests] in the control group and 3.0 eligible cardiac arrests (SD 2.3 eligible cardiac arrests) in the
LUCAS-2 group over the study period.
Recruitment of patients
Patients were recruited between 15 April 2010 and 10 June 2013. Recruitment began first in the West
Midlands (start date 15 April 2010) and, subsequently, in the other regions (start dates: Wales, September
2011; South Central, October 2011; North East, May 2012). During the recruitment period there were
16.019 cardiac arrests attended by vehicles from participating stations and trial vehicles attended 11,171
emergency incidents. Cardiac arrest was confirmed and resuscitation was attempted in 4689 cases, of
which 218 cases were ineligible and excluded. In total, 4471 patients were therefore enrolled in the study
(Figure 6).
In the LUCAS-2 arm, 638 cases received manual chest compression and in the control arm 11 cases
received LUCAS-2 chest compression (see footnote a to Figure 6).
The majority of patients were recruited in the West Midlands (2723/4471, 60.9%), with smaller
proportions in the other three regions. RRVs were the first vehicle in attendance for 1635 out of 4471
(36.6%) recruits, whereas ambulances were the first vehicle on scene for 2836 out of 4471 (63.4%)
recruits (Table 4).
Differences in baseline characteristics between the groups were small (Table 5). Slightly more patients in
the manual CPR group had cardiac arrest at home [2336/2819 (82.9%) vs. 1336/1652 (80.9%)] and
witnessed arrest [1749/2819 (62.0%) vs. 1001/1652 (60.6%)].
Cumulative recruitment through time is shown in Figure 7.
Excluded
(number of vehicles n = 104)
Non-trial vehicles (could 
not fit LUCAS, did not 
go to CAT A)
Assessed for eligibility
(number of vehicles n = 552)
Randomised
(n = 418)
Allocated to control
(n = 271)
• Attended no CA, n = 25 (9.2%)
• Attended at least 1 CA, n = 246 (90.8%)
• Delivered allocated intervention (n = 246)a
• Did not deliver allocated intervention (n = 11)a
Allocated to LUCAS
(n = 147)
• Attended no CA, n = 17 (11.2%)
• Attended at least 1 CA, n = 130 (88.4%)
• Delivered allocated intervention (n = 125)a
• Did not deliver allocated intervention (n = 123)a
FIGURE 4 The Consolidated Standards of Reporting Trials (CONSORT) diagram for vehicles. a, A vehicle can be
counted twice, as it can deliver/not deliver intervention on different occasions. Seventy-two (17%) of vehicles
changed status. CA, cardiac arrest; CAT A, category A call.
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TABLE 4 Number of recruits by region and type of vehicle
Region
Treatment arm
Total number
of patients
(percentage
of total)
LUCAS-2 Control
Ambulance RRV Total Ambulance RRV Total
North East 80 106 186 226 131 357 543 (12.1%)
South Central 105 43 148 238 121 359 507 (11.3%)
Wales 230 116 346 231 121 352 698 (15.6%)
West Midlands 648 324 972 1078 673 1751 2723 (60.9%)
Total (percentage
of total)
1063 (64.3%) 589 (35.7%) 1652 1773 (62.9%) 1046 (37.1%) 2819 4471
Recruited
(n = 418 clusters)
Emergency incidents attended
(n = 11,171 patients)
Recognition of life extinct/no
resuscitation attempted
(n = 6482)
Excluded
(n = 1)
Survival unknown
Excluded patients
(n = 218)
• Pregnant, n = 2
• Trauma, n = 107
• Aged < 18 years, n = 107
• Not out of hospital, n = 9
Assessed for eligibility
(n = 4689 patients)
Enrolled
(n = 4471 patients)
Allocated to CONTROL
 (n = 271 clusters; 2819 patients)
• Received manual chest 
   compressions, n = 2808 (99.6%)
• Received LUCAS-2 chest 
   compressions, n = 11 (0.4%)
Followed up to 3 and
12 months (survival)
(n = 2818)
Analysed
(n = 2818)
Allocated to LUCAS-2
 (n = 147 clusters; 1652 patients)
• Received LUCAS-2 chest 
   compressions, n = 985 (59.6%)
• Received manual chest 
   compressions,a n = 638 (38.6%)
• Intervention received 
   unknown, n = 29
Followed up to 3 and
12 months (survival)
(n = 1652)
Analysed
(n = 1652)
FIGURE 6 Patient flow chart. a, Reasons that the LUCAS-2 device was not used: crew not trained, 78; crew error, 168;
no device in vehicle, 26; unsuitable patient, 102 [patient too large, 58; patient too small, 22; other reasons (e.g. chest
deformity), 22]; device issues, 14; not possible to use device, 140; and reason unknown, 110. Reasons for the LUCAS-2
device use in control arm were crew error.
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Treatment
A substantial proportion of the patients who were randomised to the LUCAS-2 group (638/1652, 38%)
did not receive mechanical chest compressions. This was expected because in clinical practice there would
be occasions in which the LUCAS-2 device would not be used and it is appropriate to include these cardiac
arrests in a pragmatic trial. The LUCAS-2 device was used for 985 out of 1652 patients (60%) in the
LUCAS-2 arm; in 29 out of 1652 (1.8%) cases the intervention used was unknown. The LUCAS-2 device
was not used for trial-related reasons in 272 cases and 256 cases of non-use were classified as being for
TABLE 5 Baseline characteristics
Characteristic
Treatment arm
LUCAS-2 (N= 1652) Manual CPR (N= 2819)
Age (years)
Mean (SD) 71.0 (16.3) 71.6 (16.1)
Sex, n (%)
Male 1039 (63.0) 1774 (62.9)
Aetiology of cardiac arrest, n (%)
Presumed cardiac 1417 (85.8) 2445 (86.7)
Respiration 125 (7.6) 191 (6.8)
Submersion 5 (0.3) 7 (0.3)
Unknown 48 (2.9) 74 (2.6)
Other (non-cardiac) 57 (3.5) 102 (3.6)
Location, n (%)
Home 1336 (80.9) 2336 (82.9)
Public place 225 (13.6) 362 (12.8)
Other 91 (5.5) 121 (4.3)
Witnessed cardiac arrest, n (%) 1001 (60.6) 1749 (62.0)
Bystander 704 (42.6) 1223 (43.4)
EMS 250 (15.1) 449 (15.9)
Non-EMS health care 47 (2.8) 75 (2.6)
Not known 0 2 (0.1)
Bystander CPR before EMS arrival, n (%) 716 (43.3) 1238 (43.9)
Not known 90 (5.5) 168 (6.0)
Time (minutes) from emergency call to vehicle arrival, median (IQR) 6.5 (4.8–9.1) 6.3 (4.6–9.2)
Initial rhythm, n (%)
VF 364 (22.0) 597 (21.2)
VT 12 (0.7) 18 (0.6)
PEA 398 (24.0) 707 (25.0)
Asystole 824 (49.9) 1384 (49.1)
Not known 54 (3.3) 113 (4.0)
Defibrillation before EMS arrival, n (%) 19 (1.2) 40 (1.9)
IQR, interquartile range.
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reasons that would occur in normal clinical practice. The reason for non-use was not known for 110 cases.
In the control arm, the LUCAS-2 device was used in 11 out of 2819 cases (0.4%) as a result of crew error.
Treatments used were similar between the trial arms, although the proportion of patients receiving
intravenous drugs was slightly higher in the LUCAS-2 group (1366/1652, 82.7%) than in the control group
(2255/2819, 80.0%) (Table 6).
Follow-up
The number of patients followed up with visits at 3 and 12 months was limited by lack of response to the
initial contact and patients declining participation in the follow-up (Table 7): 146 out of 278 survivors
(52.5%) were followed up at 3 months and 143 out of 264 survivors (54.2%) at 12 months. The proportion
of patients visited was slightly lower in the LUCAS-2 group than in the control group (49.0% vs. 54.1%),
raising the possibility that there may have been differential losses between the trial arms (Table 8).
TABLE 6 Treatment of cardiac arrest
Treatment
Treatment arm, n (% of total)
LUCAS-2 (N= 1652) Manual CPR (N= 2819)
Intravenous drugs given 1366 (82.7) 2255 (80.0)
Not known 8 (0.5) 14 (0.5)
Intubated 749 (45.3) 1297 (46.0)
Not known 33 (2.0) 48 (1.7)
LMA/supraglottic airway device used 435 (26.3) 736 (26.1)
Not known 29 (1.9) 47 (1.7)
Transported to hospital 1099 (66.5) 1868 (66.2)
Status at handover
ROSC 377 (22.8) 658 (23.3)
CPR in progress 640 (38.7) 1081 (38.4)
Unknown 82 (5.0) 129 (4.6)
Received allocated intervention 985 (59.6) 2808 (99.6)
Did not receive allocated intervention 638 (38.6) 11 (0.4)
Not known whether or not allocated intervention delivered 29 (1.8) 0 (0.0)
Reasons for non-use of LUCAS-2 device
Reason unknown 110
Not trained 78
Crew error 168
Not possible to use the LUCAS-2 device 140
No device in vehicle 26
Unsuitable patient 102
Device issues 14
LMA, laryngeal mask airway.
DOI: 10.3310/hta21110 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 11
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Gates et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
31
TABLE 7 Number of patients included and not included in 3- and 12-month follow-up
Follow-up
Treatment arm, n (% of total)
Total, n (% of total)
(N= 4471)LUCAS-2 (N= 1652) Control (N= 2819)
From hospital discharge to 3-month follow-up
Deceased prior to 3-month follow-up 1556 (94.2) 2636 (93.5) 4192 (93.8)
Death/alive status unknown 0 (0.0) 1 (0.0) 1 (0.0)
3-month follow-up
Alive at 3-month follow-up 96 (5.8) 182 (6.5) 278 (6.2)
Follow-up complete (3-month visit done) 47 (2.8) 99 (3.5) 146 (3.3)
Patient declined (when contacted) 19 (1.2) 36 (1.3) 55 (1.2)
Lost to follow-up 28 (1.7) 47 (1.7) 75 (1.7)
Patient died (before visit could be done) 2 (0.1) 0 (0.0) 2 (0.0)
From hospital discharge to 12-month follow-up
Deceased prior to 12-month follow-up 1563 (94.6) 2643 (93.8) 4206 (94.1)
Death/alive status unknown 0 (0.0) 1 (0.0) 1 (0.0)
12-month follow-up
Alive at 12-month follow-up 89 (5.4) 175 (6.2) 264 (5.9)
Follow-up complete (12-month visit done) 48 (2.9) 95 (3.4) 143 (3.2)
Patient declined (when contacted) 17 (1.0) 33 (1.2) 50 (1.1)
Lost to follow-up 23 (1.3) 43 (1.5) 66 (1.5)
Withdrew 1 (0.1) 4 (0.1) 5 (0.1)
Patient died (before visit could be done) 0 (0.0) 0 (0.0) 0 (0.0)
TABLE 8 Baseline characteristics for all those patients with 3-month data (N= 146)
Characteristic
Treatment arm
LUCAS-2 (N= 47) Control (N= 99)
Age (years)
Mean (SD) 60.6 (14.7) 63.1 (14.1)
Sex
Male, n (%) 35 (75) 73 (74)
Aetiology of cardiac arrest, n (%)
Presumed cardiac 42 (89.4) 94 (95.0)
Traumatic 0 (0.0) 0 (0.0)
Respiration 5 (10.6) 3 (3.0)
Submersion 0 (0.0) 0 (0.0)
Unknown 0 (0.0) 0 (0.0)
Other (non-cardiac) 0 (0.0) 2 (2.0)
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Outcomes: intention-to-treat analysis
Survival status could not be ascertained for one patient, who was from overseas and returned home
< 30 days after the cardiac arrest, but it was known up to 12 months for all of the other participants.
In the ITT analysis, 30-day survival was similar in the LUCAS-2 and control groups [LUCAS-2, 104/1652
(6.3%); control, 193/2818 (6.8%); adjusted OR 0.86, 95% CI 0.64 to 1.15].
The analyses did not show a clear advantage to the LUCAS-2 group for any outcome; there was very little
effect of the LUCAS-2 device on ROSC (OR 0.99, 95% CI 0.86 to 1.14) and survived event (OR 0.97,
95% CI 0.82 to 1.14), but for survival at 30 days, 3 months and 12 months the point estimates favoured
manual chest compression, although the 95% CIs included 1. The number of patients surviving with a
favourable neurological outcome (i.e. a CPC score of 1 or 2) was lower in the LUCAS-2 group than in the
control group (adjusted OR 0.72, 95% CI 0.52 to 0.99; Table 9).
TABLE 8 Baseline characteristics for all those patients with 3-month data (N= 146) (continued )
Characteristic
Treatment arm
LUCAS-2 (N= 47) Control (N= 99)
Location, n (%)
Home 26 (55.3) 57 (57.6)
Public place 16 (34.0) 34 (34.8)
Other 5 (10.6) 8 (8.1)
Not known 0 (0.0) 0 (0.0)
Witnessed cardiac arrest, n (%) 40 (85.1) 90 (90.9)
Bystander 24 (60.0) 52 (57.8)
EMS 15 (37.5) 34 (37.8)
Non-EMS health care 1 (2.5) 4 (4.4)
Not known 2 (4.2) 3 (3.0)
Bystander CPR before EMS arrival, n (%) 18 (38.8) 36 (36.4)
Not known 0 (0.0) 5 (5.1)
Time (minutes) from emergency call to vehicle arrival
Median 5.9 5.9
IQR 4.2–7.0 4.3–8.2
Range 2.5–56.8 2.1–30.4
Initial rhythm, n (%)
VF 37 (78.7) 79 (79.8)
VT 3 (6.4) 3 (3.0)
PEA 4 (8.5) 10 (10.1)
Asystole 2 (4.3) 2 (2.0)
Not known 1 (2.1) 5 (5.1)
Defibrillation before EMS arrival, n (%) 1 (2.1) 2 (2.0)
Not known 0 (0.0) 1 (1.0)
IQR, interquartile range.
DOI: 10.3310/hta21110 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 11
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Gates et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
33
Complier average causal effect analyses
The CACE 1 analysis included cases for which the LUCAS-2 device was not used in situations when it
would not be used in normal clinical practice. Its results were similar to the ITT analysis, which suggests
that there is no advantage to the LUCAS-2 device when used as it would be in routine clinical practice.
In the CACE 2 analysis, which included only cases for which the LUCAS-2 device was actually used in the
intervention group, the effects of the LUCAS-2 device, again, were similar to the ITT analysis, although the
estimate for survival with a CPC score of 1 or 2 was slightly more extreme. Therefore, there was not a
substantial difference in the treatment effect of the LUCAS-2 device when it was actually used. A concern
with the ITT analysis is that because it includes a large number of non-compliant cases, any benefit among
patients for whom the device was actually used would be diluted by a lack of effect among cases that
were non-compliant, leading to underestimation of the treatment effect. The CACE analyses demonstrate
that the lack of advantage to the LUCAS-2 device in the ITT analysis is not due to dilution of the treatment
effect (Table 10).
Subgroup analyses
In the subgroup analyses there was no evidence of different treatment effects between the subgroups
for 30-day survival according to whether or not the cardiac arrest was witnessed; the type of vehicle
TABLE 9 Outcomes: adjusted ORs are adjusted for age, sex, response time, bystander CPR and initial rhythm
Outcome
Treatment arm, n (% of total) OR (95% CI)
LUCAS-2
(N= 1652)
Control
(N= 2819) Unadjusted Adjusted
Survival to 30 days 104 (6.3) 193 (6.9) 0.91
(0.71 to 1.17)
0.86
(0.64 to 1.15)
Not known 0 (0.0) 1 (0.04)
ROSC 522 (31.6) 885 (31.4) 1.02
(0.89 to 1.16)
0.99
(0.86 to 1.14)
Not known 58 (3.5) 82 (2.9)
Survived event 377 (22.8) 658 (23.3) 0.97
(0.83 to 1.14)
0.97
(0.82 to 1.14)
Not known 82 (5.0) 129 (4.6)
Survival to 3 months 96 (5.8) 182 (6.5) 0.89
(0.69 to 1.15)
0.83
(0.61 to 1.12)
Not known 0 (0.0) 1 (0.04)
Survival to 12 months 89 (5.4) 175 (6.2) 0.86
(0.60 to 1.12)
0.83
(0.62 to 1.11)
Survival with favourable neurological
outcome (CPC score of 1 or 2)
77 (4.7) 168 (6.0) 0.77
(0.59 to 1.02)
0.72
(0.52 to 0.99)
CPC (%)
1 67 (4.1) 153 (5.4)
2 10 (0.6) 15 (0.5)
3 14 (0.9) 10 (0.4)
4 2 (0.1) 1 (0.0)
5 1556 (94.2) 2636 (93.5)
Not known 3 (0.2) 4 (0.1)
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(ambulance or RRV); whether or not the patient received bystander CPR; aetiology; and region (Table 11).
In the subgroup analysis by initial rhythm, there was a difference in treatment effect between patients with
a shockable initial rhythm and those with PEA or asystole. Survival was lower in the LUCAS-2 group than
in those with shockable initial rhythms (OR 0.71, 95% CI 0.52 to 0.98), but higher in the PEA/asystole
group (OR 1.38, 95% CI 0.80 to 2.36).
TABLE 10 Results of CACE analysis
Survival
CACE analysis
CACE 1 CACE 2
Treatment arm,
n/N (% of total)
OR (95% CI)
Treatment arm,
n/N (% of total)
OR (95% CI)LUCAS-2 Control LUCAS-2 Control
To 30 days 81/1241
(6.5)
153/2155
(7.1)
0.92 (0.69 to 1.21) 50/985
(5.1)
99/1710
(5.8)
0.87 (0.61 to 1.23)
With a CPC
score of 1 or 2
62/1238
(5.0)
142/2151
(6.6)
0.76 (0.56 to 1.03) 38/983
(3.9)
101/1701
(5.9)
0.65 (0.45 to 0.96)
Survived event 297/779
(38.1)
527/1378
(38.2)
0.97 (0.84 to 1.18) 232/632
(36.7)
413/1077
(38.4)
0.96 (0.79 to 1.16)
TABLE 11 Subgroup analyses for primary outcome (30-day survival)
Comparison Subgroup
Treatment arm, n/N (% of total)
OR (95% CI)
Test of interaction
(p-value)LUCAS-2 Control
Initial rhythm VF/VT 69/376 (18.4) 148/615 (24.1) 0.71 (0.52 to 0.98) 0.0390
PEA/asystole 24/1222 (2.0) 30/2091 (1.4) 1.38 (0.80 to 2.36)
Rhythm not known 11/54 (20.4) 15/113 (13.3) –
Witnessed
status
Witnessed 89/1001 (8.9) 163/1749 (9.3) 0.96 (0.73 to 1.25) 0.6105
Not witnessed 10/528 (1.9) 21/864 (2.4) 0.78 (0.36 to 1.66)
Witnessed status
not known
123 (7.4) 206 (7.3) –
Bystander CPR Given 42/716 (5.9) 68/1238 (5.5) 1.07 (0.72 to 1.59) 0.3656
Not given 59/846 (7.0) 115/1413 (8.1) 0.86 (0.61 to 1.17)
Not known 90 168 –
Type of vehicle Ambulance 60/1063 (5.6) 127/1773 (7.7) 0.78 (0.56 to 1.06) 0.0928
Rapid response car 44/589 (7.5) 66/1045 (6.3) 1.20 (0.81 to 1.78)
Region A 16/186 (8.6) 23/357 (6.4) 1.37 (0.70 to 2.66) 0.5217
B 9/149 (6.1) 33/359 (9.2) 0.64 (0.30 to 1.37)
C 19/346 (5.5) 22/352 (6.3) 0.87 (0.46 to 1.64)
D 60/972 (6.2) 115/1750 (6.6) 0.94 (0.68 to 1.29)
Aetiology Presumed cardiac 91/1417 (6.4) 173/2445 (7.1) 0.90 (0.69 to 1.17) 0.1287
Other 9/130 (6.9) 7/198 (3.5) 2.03 (0.74 to 5.59)
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The analyses of age and response time using fractional polynomial models did not show any interaction
effects of these variables with the treatment effect of the LUCAS-2 device. Therefore, we did not find any
evidence that the treatment effect of the LUCAS-2 device differs depending on the age of the patient or
ambulance service response time.
Serious adverse events
Seven clinical AEs were reported in the LUCAS-2 group (three events of chest bruising, two of chest
laceration and two of blood in mouth). No SAEs were reported. Fifteen device incidents occurred during
operational use (four incidents in which alarms sounded, seven in which the device stopped working and
four other device incidents). No adverse or SAEs were reported in the control group.
Follow-up at 3 months and 12 months
We considered using multiple imputation (MI) to attempt to correct for the effects of missing data, but we
felt that the assumptions of any imputation procedure were unlikely to hold, given the large number of
missing data and the high probability that missingness was related to outcome. Analyses therefore used
available cases only, with no imputation.
At the 3-month follow-up (Table 12), SF-12 mental and physical scores and EQ-5D quality-of-life scores
were slightly lower in the LUCAS-2 group than in the control group.
In the 12-month follow-up (Table 13), all of the results were in the same direction, indicating worse
outcomes in the LUCAS-2 group. For some of the outcomes, the 95% CIs excluded zero, whereas for
others the data were compatible with a zero or small positive effect.
All of the follow-up results should be interpreted cautiously because of the low percentage of patients
known to be alive who were included in the follow-up. This was caused by refusal of consent and
non-response to the invitation to participate in the follow-up and led to high numbers of missing data,
with a consequent risk of bias. It is possible that those who declined to take part and those who did not
TABLE 12 Outcome at 3 months for SF-12 and EQ-5D: higher scores indicate better outcomes
Outcome
Treatment arm Difference (95% CI)
LUCAS-2 (N= 47) Control (N= 99) Unadjusted Adjusted
SF-12 physical
Mean score (SD) 38.9 (11.5) 41.7 (10.9) –2.8 (–6.7 to 1.1) –3.0 (–7.0 to 1.1)
Median score (IQR) 40.8 (32.1– 48.0) 42.6 (34.7–49.4)
Missing scores, n 2 2
SF-12 mental
Mean score (SD) 47.3 (13.4) 48.9 (10.5) –1.6 (–5.6 to 2.5) –1.5 (–5.5 to 2.6)
Median score (IQR) 51.7 (38.2–57.3) 50.2 (42.1–57.2)
Missing scores, n 2 2
EQ-5D
Mean score (SD) 63.8 (23.5) 72.0 (18.0) –8.2 (–15.1 to –1.3) –6.8 (–13.7 to 0.1)
Median score (IQR) 65.0 (50.0–80.0) 75.0 (64.0–85.0)
Missing scores, n 0 0
Mean difference are adjusted for age, sex, rhythm, bystander CPR and response time.
IQR, interquartile range.
TRIAL RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
36
respond may have had worse outcomes than those who responded. Slightly fewer people were followed
up in the LUCAS-2 group, which could have been as a result of worse outcomes in that group.
The results of the ‘quality of CPR study’ are shown in Table 14. Data recording problems in one ambulance
service meant that only compression depth was analysable from this service, so data for both compression
rate and compression fraction were available from only three services.
TABLE 13 Outcomes at 12 months. For SF-12, EQ-5D and MMSE higher scores indicate better outcomes. For PCL-C
and HADS, lower scores indicate better outcomes
Outcome
Treatment arm Difference (95% CI)
LUCAS-2 (N= 48) Control (N= 95) Unadjusted Adjusted
SF-12 physical
Mean score (SD) 40.1 (12.7) 43.8 (10.7) –3.8 (–7.8 to 0.2) –3.5 (–7.4 to 0.4)
Median score (IQR) 40.7 (30.8–51.0) 44.9 (36.1–52.5)
Missing scores, n 1 2
SF-12 mental
Mean score (SD) 47.5 (11.5) 49.4 (11.8) –1.8 (–5.9 to 2.3) –1.5 (–5.5 to 2.5)
Median score (IQR) 48.9 (42.9–55.3) 50.8 (42.7–59.1)
Missing scores, n 1 2
EQ-5D
Mean score (SD) 68.3 (22.0) 75.0 (17.4) –6.7 (–13.3 to –0.1) –6.4 (–13.1 to 0.3)
Median score (IQR) 72.0 (54.5–87.5) 80.0 (64.0–90.0)
Missing scores, n 0 0
MMSE
Mean score (SD) 26.9 (3.7) 28.0 (2.3) –1.1 (–2.2 to –0.1) –1.5 (–2.6 to –0.4)
Median score (IQR) 28.0 (27.0–29.0) 29.0 (27.0–30.0)
Missing scores, n 1 1
HADS anxiety
Mean score (SD) 6.7 (4.8) 5.7 (4.2) 0.9 (–0.6 to 2.5) 0.6 (–0.9 to 2.1)
Median score (IQR) 6.0 (3.0–10.0) 6.0 (2.0–8.0)
Missing scores, n 0 0
HADS depression
Mean score (SD) 5.8 (4.4) 4.4 (3.5) 1.4 (0.1 to 2.8) 1.1 (–0.2 to 2.5)
Median score (IQR) 5.0 (2.0–9.0) 4.0 (1.0–7.0)
Missing scores, n 0 0
PCL-C
Mean score (SD) 32.0 (12.9) 30.2 (11.0) 1.8 (–2.4 to 5.9) 1.6 (–2.6 to 5.7)
Median score (IQR) 28.0 (22.0–36.0) 28.0 (20.0–38.0)
Missing scores, n 3 2
IQR, interquartile range.
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Compression depth was fairly consistent across services, with the mean varying between 41 and 49.4 mm.
Mean compression rate was substantially faster in one service than the other two that had data, and
exceeded the guideline recommended rate of 120 compressions per minute. Compression fraction was
very consistent across the three services that had data, at between 65% and 66%.
TABLE 14 Results of quality of CPR manikin study
Ambulance
service
Number of
personnel
Depth (mm),
mean (SD)
Rate (compressions/minute),
mean (SD)
Compression fraction,
mean (SD)
A 155 49.4 (8.0) 131.8 (15.1) 65.5 (9.0)
B 157 45.0 (6.8) 119.4 (10.4) 65.4 (11.4)
C 73 41.0 (4.8) 117.6 (13.5) 65.9 (9.1)
D 103 48.6 (8.4) a a
a Not estimable because of data errors.
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Chapter 4 Mechanical chest compression for
out-of-hospital cardiac arrest: systematic review and
meta-analysis
Introduction
At the time that the PARAMEDIC trial was initiated, we were aware of two other planned or ongoing trials of
mechanical chest compression devices70,71 and two that had been published.32,72 These trials used either the
LUCAS device (original version of the battery-powered LUCAS-2) or the AutoPulse (ZOLL Medical Corporation,
Chelmsford, MA, USA), which uses a load-distributing band system. A wide band fits around the chest, and
its circumference is alternately shortened and lengthened, providing rhythmic chest compressions.
The two other large RCTs have recently been reported.71,73 It is therefore useful to summarise the overall
evidence for mechanical chest compression devices in OHCA in a systematic review and, where
appropriate, meta-analysis.
Methods
Studies were eligible for inclusion if they were individually randomised or cluster randomised trials that
compared the use of a mechanical chest compression device with standard manual chest compression in
adult patients following OHCA. There was no restriction of eligibility based on language of publication.
Quasi-randomised trials, for example those whose participants were randomised by birth date or days of the
week, were excluded. Studies were not included in analyses if they reported insufficient information to allow
assessment of their risk of bias. Screening, decisions about inclusion and data extraction were performed by
one author and checked by a second author. The review protocol was not preregistered or published.
We searched electronic resources (MEDLINE, EMBASE and the Cochrane Central Register of Controlled
Trials from 1990 to February 2015) and the reference lists of studies and review articles (last search
February 2015). We based our search strategies on that published by the Cochrane review of mechanical
chest compression devices,74 which used a combination of search terms to describe the condition (cardiac
arrest), the intervention (mechanical compression devices) and the study design (RCTs) (see Appendix 9).
For each eligible study, we extracted information about the study’s population and methodology, and the
following outcomes: ROSC; survived event (sustained ROSC until handover to a hospital emergency
department); survival to hospital discharge or 30 days; and survival with good neurological outcome. Good
neurological outcome was defined as either a CPC score of 1 or 2 or a mRS score of between 0 and 3.75
When studies presented a treatment effect estimate that was adjusted for important covariates (e.g.
clustering, initial rhythm, bystander CPR, EMS response time, age), we used this estimate in meta-analyses
in preference to unadjusted results.
We used the Cochrane risk-of-bias tool to assess studies’ risk of bias. This assesses seven domains:
(1) generation of random allocation sequence; (2) allocation concealment; (3) blinding of participants and
study personnel; (4) blinding of outcome assessment; (5) incomplete outcome data; (6) selective reporting;
and (7) other sources of bias. For each study, we assessed the methods that were used to address each
potential source of bias and summarised them in tabular form. We did not produce an overall bias risk
judgement or score, but assessed each domain separately (Table 15).
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We combined studies using Review Manager software version 5.3 (RevMan, The Cochrane Collaboration,
The Nordic Cochrane Centre, Copenhagen, Denmark). As there may be differences in treatment effect
between trials, especially those using different devices, we used a random-effects model. We used the
generic inverse variance method in RevMan to estimate the average treatment effect (OR) for each
outcome, and the uncertainty around it, measured by the 95% CI. We also calculated 95% prediction
intervals76 to estimate the range of plausible treatment effects. We quantified heterogeneity in each
analysis by the τ2-statistic and I2-statistic. Studies were subgrouped by the type of mechanical compression
device that was used, as different devices operate in different ways and hence could have different
treatment effects. Our primary analysis compared mechanical compression with manual compression, and
we performed a subgroup analysis by type of device to explore whether or not there was any evidence
that treatment effects differed between devices.
Some of the included trials presented several results using different adjustments for covariates and design
elements. We performed sensitivity analyses to explore the effects of using differently adjusted results for
these trials. In addition, the PARAMEDIC trial71 presented CACE estimates, to estimate the treatment effect
in the presence of non-compliance.75,76 We performed additional sensitivity analyses to explore the effects
of using these estimates.
Results
The search located five eligible studies55,67,69–71 (Figure 8).
Two trials55,69 evaluated the AutoPulse device and three trials67,70,71 evaluated the LUCAS device. Two of the
studies55,71 used a cluster randomised design: one study (PARAMEDIC)71 randomising by ambulance service
vehicles and the other study [AutoPulse Assisted Prehospital International Resuscitation (ASPIRE)]55 using
ambulance stations or groups of stations as the clusters; this study55 also incorporated crossovers at
prespecified points between the intervention and control groups. The other three studies67,69,70 utilised
individual randomisation, using sealed envelopes or cards carried with the device, which were accessed by
the paramedic at the time of the resuscitation attempt.
There were a number of differences between the studies in addition to the chest compression device used,
which may have caused differences in treatment effects and hence introduced heterogeneity into the
meta-analyses. In two studies,67,70 the LUCAS-2 device was used as part of a modified treatment algorithm,
whereas in the third LUCAS-2 study,71 mechanical chest compression was simply used to replace manual
compression in the standard algorithm. One of the trials of AutoPulse conducted extensive training to
optimise the quality of manual CPR that was provided to the control group;77 in contrast, other trials did
Reports retrieved by search
(n = 345)
Included in review
(n = 5)
Full-text articles assessed
for eligibility
(n = 7)
Records excluded
(duplicate or not relevant)
(n = 338)
Full-text articles excluded
(n = 2)
• In-hospital study, n = 1
• Quasi-randomised, n = 1
FIGURE 8 Flow chart of studies.
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not provide extra training, but the control group received CPR as it would be provided in standard
clinical practice.
The randomisation methods of the studies appeared to be adequate, although four studies did not provide
any information on the generation of the random allocation sequence.55,67,69,70 One concern with individual
randomisation was that it would be possible for ambulance staff to open randomisation envelopes early
and subvert the randomisation scheme. No studies reported any problems with individual randomisation
procedures, such as missing randomisation cards that could not be accounted for (which might indicate that
crews had selected the intervention) or large numbers of eligible patients who were not recruited (which
might suggest that the crew felt that the randomised allocation would not be good for the patient).
Blinding of clinicians providing care was clearly not possible and participants who survived may also have
been aware of which allocation they had received. For example, use of the LUCAS-2 device may leave
characteristic marks on the patient’s chest. The assessment of survival outcomes was unlikely to have been
affected by whether or not the people assessing the outcome were blinded. One study71 stated that
personnel assessing neurological status (via the CPC or mRS) were blinded; in other studies, this was
unclear. It is conceivable that knowledge of treatment allocations could influence assessments of
neurological status; if assessors had strong views on the effectiveness of the intervention being tested, they
may have adjusted their threshold for allocating a patient to a mRS or CPC category. We cannot exclude
this potential bias in studies for which outcome assessment was not blinded.
In all of the trials, the proportion of missing outcome data was low, when measured as a percentage of all of
the study participants. However, in some trials, there was potentially bias because of missing data in the
assessment of neurologically intact survival. This was because the missing data were concentrated among
survivors; for example, in the Circulation Improving Resuscitation Care (CIRC) trial,71 although only 2.8% of
participants had missing mRS data, they represented 27.7% of survivors. The populations included varied
between trials. In the ASPIRE study,55 results were presented for a prespecified ‘primary’ population
(patients who were in cardiac arrest at the time of EMS arrival and whose cardiac arrest was considered to
be of cardiac origin). Patients who fulfilled exclusion criteria were treated according to trial allocation, but
subsequently excluded (in order not to introduce delays to treatment); however, 304 ‘non-primary’ cases
were also excluded from the main results. In the CIRC trial,71 there were also 522 post-randomisation
exclusions of patients fulfilling exclusion criteria. However, this trial69 also excluded patients recruited in a
prespecified run-in phase, an unspecified number of patients recruited early in the trial (after the run-in
period) when compliance with AutoPulse was found to be poor as a result of battery issues and data from
one site for a 3-month period when that site was non-compliant with the study protocol (number not stated).
The CIRC69 trial used a group sequential design, with predefined stopping boundaries for superiority,
inferiority and equivalence (double triangular test).77,78 The trial report presented treatment effect estimates
that were adjusted for clinical covariates for all outcomes, but additionally adjusted the primary outcome
(survival to hospital discharge) for the sequence of interim analyses. In this review we have used the results
adjusted for covariates, but not for the interim analyses, because these are consistent and based on the
data rather than the decision-making process. We explored the effect of the adjustment of the primary
outcome for interim analyses with a sensitivity analysis.
The meta-analyses (see Figures 9–12) do not suggest an advantage to mechanical chest compression,
using either device, for any of the outcomes. CIs and prediction intervals were wide, reflecting the low
incidence of favourable outcomes after OHCA and consequent imprecision of treatment effect estimates.
For ROSC (Figure 9), although there was no evidence of an overall difference between mechanical and
manual chest compression (average OR 0.96, 95% CI 0.85 to 1.10, 95% prediction interval 0.66 to 1.41),
there was some evidence that the effects of the LUCAS-2 and AutoPulse devices were different
(I2 = 78.5% for subgroup differences). There were data from only one AutoPulse trial,69 but that suggested
a lower proportion achieving ROSC in the mechanical chest compression group.
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Survival of event was reported only by trials that used the LUCAS-2 device (Figure 10). The results were
consistent across trials and suggested no advantage to mechanical chest compression devices (OR 0.95,
95% CI 0.85 to1.07; 95% prediction interval 0.45 to 2.00).
The analysis of survival to discharge or 30 days (Figure 11) again suggested no advantage to mechanical
chest compression (OR 0.89, 95% CI 0.77 to 1.02; 95% prediction interval 0.71 to 1.12). The point
estimate was in the direction of favouring manual chest compression and the upper 95% confidence limit
was only just > 1. There was no evidence of heterogeneity of treatment effects. A sensitivity analysis using
the estimate for the CIRC trial,71 adjusted for interim analyses as well as covariates, did not make a major
difference to the overall average treatment effect (OR 0.94, 95% CI 0.79 to 1.11; 95% prediction interval
0.62 to 1.43). Similarly, sensitivity analyses using the CACE estimates for the PARAMEDIC trial71 did not
make a substantial difference to the overall result.
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FIGURE 9 Return of spontaneous circulation. IV, inverse variance; SE, standard error.
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FIGURE 10 Survived event (i.e. sustained ROSC to handover to hospital emergency department). IV, inverse variance.
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Results for survival with good neurological outcome (Figure 12) were more heterogeneous than for other
outcomes (I2 = 68%). This was not due to differences between the LUCAS-2 and AutoPulse devices, which
were small (I2 = 11% for subgroup differences), but to inconsistency between the results of the two trials
of each device. Reasons for the inconsistency were unclear. Overall, there was no evidence that the
average treatment effect favoured mechanical chest compression, but the 95% prediction interval was very
wide (OR 0.76, 95% CI 0.53 to 1.11; 95% prediction interval 0.17 to 3.49).
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FIGURE 11 Survival to discharge from hospital or 30 days. IV, inverse variance.
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FIGURE 12 Survival with CPC score of 1–2 or mRS score of 0–3. IV, inverse variance.
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Discussion
The trials recruited unselected populations of patients, which were typical of clinical practice in the
geographical areas in which they were conducted. Despite the large size of many of the trials included in
the review, CIs around the combined treatment effect estimates were relatively wide because of the low
survival rate from OHCA. The methodological quality of the included studies was generally good. Secure
methods of randomisation were used and for most outcomes there were few missing data. Trials using a
cluster randomised design were unable to conceal allocations in advance of assignment and ambulance
crews would have been aware of the allocation. This could have led to inclusion bias, in two ways. First,
patients might not be reported to the trial if it was felt that they were not receiving the best allocation.
The PARAMEDIC trial71 guarded against this by including all eligible cardiac arrests that were attended
by trial vehicles. It was not clear whether or not this was also the case in the ASPIRE study.55 Second,
the threshold for initiating a resuscitation attempt could have varied according to the intervention. For
example, if a crew believed strongly that mechanical chest compression was better, they might initiate
a resuscitation attempt in a situation in which they would not attempt resuscitation if manual chest
compression was to be used. In the PARAMEDIC trial,71 the DMC reviewed evidence for differential
thresholds for resuscitation but did not find evidence of any appreciable selection bias.
The use of the double triangular test design in the CIRC69 trial raises a number of issues. The adjustment of
the final analysis to allow for the interim analyses had a large effect on the primary outcome (survival to
hospital discharge), changing the point estimate of the OR from 0.89 to 1.06. The secondary analyses
were not adjusted for the interim analyses, so the results for the primary and secondary outcomes were
not directly comparable. In addition, the boundaries for equivalence in the double triangular test were very
generous; if the ‘equivalence’ boundary was crossed, the 95% CI would be contained between log odds
of –0.37 and 0.37 (i.e. an OR of 0.69 and 1.45).69 This interval includes values that would represent
substantial benefit and substantial harm, so the conclusion of ‘equivalence’ in this situation is questionable.
In some trials, data for neurologically intact survival were missing for a high proportion of survivors. This
was most severe in the CIRC trial,71 in which data for this outcome were lacking for 27.7% of survivors.
This reflects the difficulty of performing follow-up assessments on cardiac arrest survivors, but clearly has
the potential to introduce bias. It is possible, or even likely, that there could be an association between
missingness and neurological outcome. There are many plausible reasons why patients with poor
outcomes may be more likely to be lost; for example, they may be harder to contact because they have
moved to a residential care facility or they may be less willing or able to undertake follow-up assessments.
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Chapter 5 Economic evaluation
Introduction
The economic evaluation was conducted to assess the cost-effectiveness of use of the LUCAS-2 device
compared with manual chest compression (manual CPR) during resuscitation by ambulance staff after
OHCA. The economic evaluation consisted of two distinct, but complementary, sets of analyses: a
within-trial analysis over the 12-month trial period and a decision-analytic model that was constructed to
extrapolate the results over the expected lifetime of the trial participants. The analyses were conducted
from the NHS and Personal Social Services (PSS) perspective and they report cost per incremental
quality-adjusted life-year (QALY) of the LUCAS-2 device compared with usual care (manual CPR).
The analyses were conducted in line with best practice guidelines.79
Methods
Within-trial analysis
The within-trial analysis aimed to determine the cost-effectiveness of the LUCAS-2 device compared with
manual chest compression over the period of the trial (i.e. from cardiac arrest to 12 months’ follow-up).
The analysis used QALYs as the main outcome and adopted the perspective of the NHS and PSS. Utility
values were derived from patient questionnaires; resource use was obtained from a variety of sources,
including the trial CRFs, large data sets (i.e. HES, ICNARC) and self-completed patient questionnaires.
Neither costs nor QALYs were discounted given the 12-month time period. The results are reported as
incremental cost-effectiveness ratios (ICERs).
Quality-adjusted life-years
Quality-adjusted life-years reflect both duration and quality of life and their estimation requires the
production of utility weights for each health state observed in the trial population. HRQL was assessed using
the EQ-5D,42 which has been validated for use in the critical care patient group.80 Surviving patients
completed the EQ-5D at 3 and 12 months post cardiac arrest. The EQ-5D responses were converted to
health-state utility values using the UK tariff.81 Utility values were combined with survival information to
calculate QALYs for the trial period using an area under the curve (AUC) approach. As patients were unable
to complete the measure at baseline, estimates had to be made of their baseline utility level. Following
strategies previously used in studies that have dealt with this scenario,82–84 we assumed that patients who
experienced a cardiac arrest had a baseline utility value of ‘0’ (which is equivalent to dead). We then
assumed a linear transition from ‘0’ to the 3-month utility value and, similarly, from the 3- to the 12-month
utility value. A utility weight of zero was assigned to patients who died within 3 months, which may
underestimate total QALYs. We explored an alternative assumption in the sensitivity analysis, for which the
survival days of these patients were assigned the average 3-month utility estimated in our sample.
Resource use and costs
The costs considered in this analysis included intervention costs (i.e. cost of the LUCAS-2 device and
ambulance costs), costs of hospital inpatient stays, accident and emergency (A&E) admissions and
outpatient visits and the use of primary care and community-based health and social care services
(such as GP and social worker visits).
Resource use data were collected prospectively and retrospectively. Hospital resource utilisation was
obtained through linkage with the HES data set. We extracted data from the HES for study participants
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from cardiac arrest to 12 months after randomisation. The data set records information on the total
number of days in hospital, the number of in-person and telephone outpatient visits and the number of
A&E admissions. To identify the number of hospital days spent in the ICU (Table 16) we used information
from the ICNARC data set. Patients who stayed for < 24 hours in hospital were also identified. Some of
these were regular admissions and, based on the profile of their procedural use, were assigned the cost of
1 day in ICU. Another group of patients who stayed for < 24 hours in hospital were recorded in HES as
day case or regular day admissions. Hospital costs were obtained by multiplying the number of days or
visits of each service by the corresponding unit cost derived from NHS reference costs databases.85
Following hospital discharge, health-care resource use questionnaires were completed by surviving patients
at 3 and 12 months post cardiac arrest. Patients were asked about their use of health and social services
during the previous 3 months, including further inpatient and outpatient care and primary and community-
based health and social services. For the 6-month period during which non-hospital resource use data
were not collected (between 3 and 9 months post cardiac arrest), we used the average resource utilisation
between the initial (0–3 months) and final (9–12 months) period. Patients who died within 3 months were
assumed to have incurred no community-based health and social care costs. Health-care resource use was
multiplied by the relevant unit costs extracted from the national reference costs (Table 17).86
A microcosting study was undertaken to establish the cost of the LUCAS-2 device and determine the
relevant cost per application. This included (1) the cost of purchasing the device and accessories; (2) the
cost of fitting the device to the ambulance; (3) maintenance costs; and (4) initial and ongoing staff training
costs. The frequency of use observed in the trial was used to estimate the expected number of applications
in order to calculate the expected cost per application (Table 18).
Missing data
The primary analysis used MI to handle missing data using baseline characteristics (sex and age) to impute
missing follow-up HRQL and resource use information. Unlike more simple imputation approaches, MI
reflects both the structural uncertainty related to the parameters of the imputation model and the
uncertainty arising from missing data. Practically, to obtain total costs and QALYs at 1 year for each
patient, missing data on HRQL and resource use were addressed using chained equations. We used
truncated models to reflect the specific distribution of HRQL and resource use and generated 10 data sets.
Estimates from each imputed data set were combined following Rubin’s rule.87 In the sensitivity analysis,
we also report results from the complete-case analysis, which included only patients with non-missing
utility values.
Cost-effectiveness analysis
The main cost-effectiveness outcome is the 1-year cost per QALY. ICERs were calculated where one
intervention was more expensive and more effective or less effective and cheaper than the other.88
TABLE 16 Summary table of ICU length-of-stay data
Patient group n Missing ICU length of stay (days) mean (SD) Source
Survived 1–30 days 588 – 3.15 (3.8) ICNARC data and assumptiona
Survived > 30 days 211 87 7.10 (17.6) ICNARC data
a ICU length of stay from ICNARC was available for 296 patients who survived 1–30 days. Most patients in this group
survived 1 or 2 days (62%) and spent their entire survival days in ICU. Patients in this group with missing ICNARC
information were therefore assumed to have spent their entire survival period in the ICU.
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TABLE 17 Unit costs used in the analysis
Resource item
Unit cost
(£) Source Details/assumptions
LUCAS device cost
per application
232 Own calculations:
see Table 18
A lifespan of 8 years was assumed
Ambulance cost 180 NHS Reference
Costs 2013–1485
‘See and treat’ (if died on scene)
231 NHS Reference
Costs 2013–1485
‘See and treat and convey’ (if did not die on scene)
Hospital-based or residential care services
ICU per day 1382 NHS Reference
Costs 2013–1485
Non-specific general adult critical care patients predominate
Average cost of 0–6 or more organs supported: SC, CCU01;
CC, XC01Z-XC07Z
Hospital inpatient stay
per day
275 NHS Reference
Costs 2013–1485
Non-elective inpatients; excess bed-days
Hospital outpatient
clinic appointment
128 NHS Reference
Costs 2013–1485
Outpatient/consultant led
Hospital A&E visit 339 NHS Reference
Costs 2013–1485
Emergency medicine, category 3 investigation with category
4 treatment: SC, T01A; CC, VB02ZZ
Nursing/residential
home per day
157 Curtis, 201286 Local authority residential care for older people
Establishment cost per permanent resident week/7 days
Primary care and community-based health and social services
GP: surgery visit 46 Curtis, 201286 Per-patient contact lasting 11.7 minutes, including direct
care staff costs
GP: home visit 92 Curtis, 201286 (Per-patient contact lasting 11.7 minutes plus 12 minutes of
travel time) × £3.90/minute cost of patient contact
District nurse/health
visitor visit
45 NHS Reference
Costs 2013–1485
Average of district nurse, face to face: SC, NURS; CC,
N02AF
Average of health visitor, face to face: SC, HVM; CC, N03G
Social worker visit 79 Curtis, 201286 One-hour appointment
Counsellor
appointment
50 Curtis, 201286 One-hour appointment
Home help session 24 Curtis, 201286 One-hour weekday session
Speech and language
therapist appointment
84 NHS Reference
Costs 2013–1485
Speech and language therapist, adult, one to one:
CC, A13A1
Psychologist
appointment
85 NHS Reference
Costs 2013–1485
Non-admitted non-face to face attendance, follow-up:
SC, 656; CC, WF01C
Day centre visit 42 Curtis, 201286 Local authority day care for older people; per client session
lasting 3.5 hours
Lunch or social
club session
7 Curtis, 201286 Same cost as 1 hour of befriending older adults programme
Meals on Wheels 7 Curtis, 201286 Assuming one contact = one meal. Average cost of per
‘meal on wheels’ for the local authority
Family Support
session
50 Curtis, 201286 Family support worker; per hour of client-related work
NHS codes: CC, currency code; SC, service code.
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The ICER is calculated by dividing the difference in mean cost between the two arms by the difference in
mean QALYs between the two arms:
ICER =
Ci−Cc
Ei−Ec
=
ΔC
ΔE
, (1)
where Ci and Ei are the cost and effectiveness of the LUCAS-2 device and Cc and Ec are the cost and
effectiveness of manual compression, and ΔC and ΔE are the incremental cost and effect of the
intervention compared with the comparator. Thus, the ICER represents the cost per QALY gained. ICERs
below the NICE willingness-to-pay threshold (λ) of £20,000 are considered to indicate cost-effectiveness.
For the main analyses, as effects were observed within 12 months, no discounting of costs or effects was
required. ITT analyses were conducted throughout.
Uncertainty and sensitivity analysis
Uncertainty was explored by conducting non-parametric bootstrapping via 1000 resampled analyses.
Cost-effectiveness planes (scatterplots of the 1000 bootstrap replications) were created.89,90 Sensitivity
analyses were conducted to determine the impact of assumptions on the cost-effectiveness results. We
compared results from complete-case analysis against MI and also carried out analyses using an average
group cost for outliers with high costs. Owing to the large number of non-compliers, results of a
TABLE 18 Cost of the LUCAS-2 device
Cost item Assumptions
Cost (£) for the
trial period
Purchase cost
(LUCAS-2 and
accessories)
A one-off purchase cost, the LUCAS-2 device and necessary accessories were
calculated using the purchase cost for the device itself, suction cups, battery,
12-V car cable and power supply for inside the ambulance. The cost of each
these items was multiplied by the number of ambulances in the intervention
trial arm. Battery chargers and a spare battery at each of the 90 stations with
the LUCAS-2 device were costed. For spare LUCAS-2 parts it was assumed
that one set of each spare would be required per 10 devices. Spare parts
included a carry bag, stabilisation strap and patient straps
148,504
Cost of fitting
LUCAS-2 to vehicles
The total cost of fitting the device to ambulance vehicles required the cost of
screws, chair strap, clips and net. One hour of labour was estimated to fit the
strap per ambulance. The cost of fitting the device to one ambulance was
then multiplied by the number of vehicles in the intervention arm
783
Maintenance
(assuming no repairs)
The planned preventative maintenance service was estimated to cost £250
for each LUCAS-2 device. This cost assumed no parts were needed and no
repairs occurred
35,750
Staff training
(initial and ongoing)
Initial staff training: it was estimated that each regional ambulance trust had
a mandatory training programme that paid paramedics 3 hours of overtime
to attend. The per-paramedic cost was multiplied by the number of staff at
each site who had been trained
Ongoing staff training: one regional ambulance site reported a 30-minute
training refresher for paramedics. It was assumed that paramedics in all sites
would receive a similar 30-minute refresher course once per year. The cost
per paramedic was multiplied by the total number of staff trained within the
initial staff training
46,450
Total costs 231,488
Number of
applications
996
Cost per application 232
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per-protocol analysis were also reported. We also derived net monetary benefits (NMBs) for each patient
using the following:
NMB = ΔEλ−ΔC. (2)
We then estimated linear regression models to identify predictors of NMB, including treatment arm.
Long-term decision-analytic model
To assess cost-effectiveness over the lifetime horizon, a decision tree combined with a Markov model was
constructed91 (Figure 13). The model starts with a decision tree reflecting patients’ risk of death at different
time points and patient CPC score at the end of the trial. The end points of the decision tree are the starting
point of the lifetime Markov model. We chose to model the intervention impact from baseline application
rather than simply extending outcomes and costs from 12 months onwards. The main motivation for this was
to enable better capture of uncertainty during the trial period and allow propagation of this through the
lifetime horizon. Beyond 1 year post cardiac arrest, costs, HRQL and survival were modelled in two subsets
of patients: patients with (1) good neurological outcomes at 1 year (CPC score of 1 or 2) and (2) poor
neurological outcomes at 1 year (CPC score of > 2). Relevant model parameters were extracted from the trial
data and from the literature (Table 19). The parameters of interest included relative survival rates in these
subgroups that were applied to UK reference mortality rates published by the Office for National Statistics
(ONS) and annual cost and HRQL data for cardiac arrest survivors with/without good neurological outcomes
(from trial data). Annual costs for patients with poor neurological outcomes were obtained from trial data
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FIGURE 13 Structure of the decision-analytic model.
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(outpatient visits and community-based health and social care) and residential care costs were added, as these
patients are likely to require daily support/institutionalisation.86
A discount rate of 3.5% was applied to costs and effects in the Markov model (see Figure 13). The
within-trial analysis was conducted using the statistical software Stata version 13.1 (StataCorp LP, College
Station, TX, USA) and the decision-analytic model was built using Microsoft Excel® (Microsoft Corporation,
Redmond, WA, USA).
Cost-effectiveness analysis
The ICER is calculated by dividing the difference in mean cost between the two arms by the difference in
mean QALYs between the two arms:
ICER =
Ci−Cc
Ei−Ec
=
ΔC
ΔE
, (3)
where Ci and Ei are the expected cost and effectiveness of the LUCAS-2 device and are the expected
cost and effectiveness of manual compression, and ΔC and ΔE are the incremental cost and effect
of the intervention compared with the comparator. Thus, the ICER represents the cost per QALY gained.
ICERs that are below the NICE willingness-to-pay threshold (λ) of £20,000 are considered to indicate
cost-effectiveness. A discount rate of 3.5% was used to discount costs and benefits.
TABLE 19 Model parameters
Parameters Group/arm Mean value Distribution Source
Decision tree
p (die on scene) Manual CPR 0.3274 Beta Trial data
LUCAS-2 0.3290
p (die within 3 months | did not
die on scene)
Manual CPR 0.9029 Beta Trial data
LUCAS-2 0.9134
p (die within 3–12 months |
survived to 3 months)
Manual CPR 0.0380 Beta Trial data
LUCAS-2 0.0729
p (good neurological
outcome | survive to 1 year)
Manual CPR 0.8605 Beta Trial data
LUCAS-2 0.7442
Markov model
Annual mortality rate Fixed ONS92
Excess mortality for patients with
poor neurological outcomes
1.67 Log-normal Phelps 201393
Discount rate 3.5% Fixed
Annual cost (£) Good neurological outcome
(CPC score of 1 or 2)
3315 Log-normal Trial data
Poor neurological outcome
(CPC score of 3 or 4)
43146 Log-normal Trial data and
Curtis, 201286
Utility Good neurological outcome
(CPC score of 1 or 2)
0.75 Beta Trial data
Poor neurological outcome
(CPC score of 3 or 4)
0.47 Beta Trial data
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Uncertainty and sensitivity analysis
We first performed several one-way sensitivity analyses by adding and subtracting 20% of the main
parameters of the model (i.e. costs, QALY and 1-year mortality) and assessed the subsequent impact on
the ICERs. The value of 20% is arbitrary, but was considered likely to represent any uncertainty that might
exist in parameter values. A probabilistic sensitivity analysis was then conducted for a more comprehensive
account of uncertainty in the model parameters. Cost-effectiveness acceptability curves (CEACs) that show
the probability of cost-effectiveness across a range of values for λ were created using the net benefit
approach.94 With this transformation, we avoid problems encountered with ICERs (same sign but opposite
quadrants) and CEACs are much simpler to calculate.95
Results
Among the 4771 patients who were enrolled in the study, 1652 were assigned to the intervention arm
(LUCAS-2) and 2819 were assigned to the control group (manual CPR). During the trial, 985 (60%)
patients in the intervention group received LUCAS-2 device treatment and 11 (< 1%) patients in the
control group received mechanical CPR.73 At 3 months, 96 (6%) patients survived in the LUCAS-2 group
and 182 (6%) survived in the control group. At 12 months, 89 (5%) patients survived in the LUCAS-2
group and 177 (6%) survived in the manual CPR group (Table 20).
One-year costs
Using the complete-case analysis, the average cost at 1 year in the LUCAS-2 group was higher than in the
manual CPR group, with an incremental cost of £106.70, with hospital costs being the main cost driver
(Table 21). Overall, the average cost in each category of costs is higher in the LUCAS-2 group than in the
manual CPR group.
We also observed higher costs in the LUCAS-2 arm than in the manual CPR arm in all cost categories in
analyses that followed MI. Using the imputed data sets, we computed the total cost incurred in each
patient group (the sum of all costs across all patients) that we divided by the number of 1-year survivors in
each group (i.e. 177 patients in the manual CPR arm and 89 patients in the LUCAS-2 arm). We obtained a
costs per 1-year survivor of £32,192 in the manual CPR arm and of £52,548 in the LUCAS-2 arm.
Quality of life
The mean utility scores in each group were measured at 3 and 12 months (Table 22). At both 3 and
12 months, HRQL was higher in the manual CPR group than in the LUCAS-2 group. An independent-sample
t-test indicated that these differences were statistically significant. Changes in HRQL between the 3- and
12-month assessments were not statistically significant. Table 22 also reports the average QALY over 1 year
accrued by all patients in both groups based on the AUC calculations. The mean 1-year QALY is small as a
TABLE 20 Completion rate of HRQL and resource questionnaires
Follow-up
Treatment arm, n (%)
Manual CPR LUCAS-2
3 months
EQ-5D 99 (54) 47 (49)
Resource use 99 (54) 46 (48)
12 months
EQ-5D 95 (54) 48 (54)
Resource use 93 (53) 46 (52)
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TABLE 21 One-year costs
Arm N n missing Mean (£) Bootstrap 95% CI (£) Minimum (£) Maximum (£)
Complete-case data
Costs to the NHS over 1 year
Manual CPR 2690 129 1294.00 1152.40 to 1435.70 0 41,945
LUCAS-2 1577 75 1400.70 1131.20 to 1670.30 0 123,660
ICU costs
Manual CPR 2762 57 959.20 826.80 to 1091.60 0 59,426
LUCAS-2 1622 30 1221.80 766.20 to 1677.50 0 317,860
Other hospital costs (A&E, outpatient, general ward)
Manual CPR 2772 47 521.50 428.60 to 614.30 0 75,767
LUCAS-2 1619 33 585.00 386.00 to 784.00 0 74,276
Hospital costs
Manual CPR 2732 87 1318.00 1136.30 to 1499.80 0 101,928
LUCAS-2 1599 53 1540.30 1083.40 to 1997.20 0 318,327
Community-based health and social care costs
Manual CPR 2716 103 31.90 23.10 to 40.60 0 8834
LUCAS-2 1593 59 91.10 21.20 to 160.90 0 50,138
Imputed data
Costs to the NHS over 1 year
Manual CPR 2819 – 2021.30 1772.30 to 2270.20 0 41,945
LUCAS-2 1652 – 2831.00 2149.60 to 3512.30 0 123,660
ICU costs
Manual CPR 2819 – 1102.10 947.00 to 1257.20 0 59,426
LUCAS-2 1652 – 1447.30 883.40 to 2011.10 0 317,860
Other hospital costs (A&E, outpatients, general ward)
Manual CPR 2819 – 604.00 478.80 to 729.10 0 75,767
LUCAS-2 1652 – 724.60 507.50 to 941.70 0 74,276
Hospital costs
Manual CPR 2819 – 1706.10 1477.50 to 1934.60 0 101,928
LUCAS-2 1652 – 2171.80 1525.60 to 2818.00 0 318,327
Community-based health and social care costs
Manual CPR 2819 – 108.80 37.90 to 179.60 0 8834
LUCAS-2 1652 – 287.40 111.80 to 463.00 0 50,138
Total costs to the NHS divided by the number of 1-year survivors
Manual CPR 177 – 32,192 28,228 to 36,156
LUCAS-2 89 – 52,548 39,908 to 65,188
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result of the high 1-year mortality rate in the sample (> 95%). We observe a small difference in mean QALY
over 1 year (0.007), with patients in the manual CPR group having a higher average QALY than patients in
the LUCAS-2 group. HRQL of survivors at 12 months was also estimated by neurological outcome status
(as measured via the CPC score). We found a significant difference in HRQL between patients with good
neurological outcome (CPC score of 1 or 2; mean 0.75) and patients with poor neurological outcome
(CPC score of 3 or 4; mean: 0.47).
Cost-effectiveness at 1 year
Table 23 presents the cost-effectiveness results, showing the incremental costs and QALY for each arm of
the trial, as well as the corresponding ICER. Results are shown for both the ITT and per-protocol analyses
and, in each case, complete-case and MI results are presented. In addition, to obtain an approximation of
the CACE, which was conducted for clinical outcomes, we inflate the ITT results using the proportion of
compliers in the sample (i.e. 60%).
At 1 year, we found an incremental QALY of –0.0072 and an incremental cost of £106.70, which indicates
that the LUCAS-2 device is dominated by manual chest compression, that is, the LUCAS-2 device is more costly
and less effective than manual chest compression. When a per-protocol analysis was conducted instead,
manual compression still dominated and results from the MI led to the same conclusion. The conclusions
TABLE 22 Health-related quality of life by treatment arm
Outcome
Treatment arm
Manual CPR LUCAS-2
Number of
participants
with data Mean 95% CI
Number of
participants
with data Mean 95% CI
Utility score among survivors
3 months 99 0.780 0.732 to 0.828 47 0.647 0.555 to 0.738
12 months 95 0.761 0.712 to 0.810 48 0.639 0.542 to 0.736
QALY over 12 months
Complete case 2741 0.026 0.021 to 0.031 1609 0.018 0.013 to 0.024
Imputed 2818 0.042 0.036 to 0.048 1652 0.033 0.026 to 0.040
TABLE 23 Incremental cost-effectiveness ratios
Analysis
Number of
participants
Incremental
ICERCost (£) QALY
MI (ITT) 4771 809.60 –0.0093 Manual CPR dominates
Complete case (ITT) 4267 106.70 –0.0072
Complete case (ITT, average group cost for outliers) 4267 39.20 –0.0067
MI (per protocol) 3793 495.90 –0.0142
Complete case (per protocol) 3391 296.40 –0.0070
Alternative QALY calculationa 4771 809.60 –0.0091
QALY derived with SF-12 (complete case) 4267 106.70 –0.0046
CACE (complete case) 4267 177.80 –0.012
a Instead of incurring no QALYs, patients who died within 3 months were imputed QALYs based on their total number of
survival days, to which a utility was assigned corresponding to the average 3-month utility in our sample.
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remain unchanged when QALYs were derived using SF-12 instead of EQ-5D. Overall, the results suggest that
manual chest compression dominated the LUCAS-2 device, with the LUCAS-2 device having higher costs and
providing lower QALY benefits than manual CPR. Interpretation, however, should be tempered by the very
small between-group differences observed in QALYs and the relatively small differences in costs.
In Figures 14 and 15, we present the results of the 1000 bootstrap replications in the cost-effectiveness
plane for both the complete-case analysis and the analysis based on MI. In both cases, the 1000 estimates
are spread mainly in the north-west quadrant of the cost-effectiveness plane, meaning that the LUCAS-2
device is more costly and less effective than manual chest compression; however, it is worth noting that
QALY losses are minimal. In other words, these results confirm the finding that the LUCAS-2 device is
dominated by manual CPR. None of the iterations is below conventional values of the threshold (£20,000
per QALY). It is worth noting that the iterations in the MI analysis are more concentrated in the north-west
quadrant (i.e. only a small number of iterations correspond to a decrease in costs). This suggests that the
complete-case analysis may underestimate the incremental costs of the LUCAS-2 device. A possible
explanation is that data of more costly (e.g. older) patients are more likely to be missing.
Net monetary benefits
Linear regression models using age, sex and treatment allocation as covariates and independent variables
were run to predict NMBs. Treatment allocation was found to be a significant predictor of NMB; NMB was
significantly smaller (more negative) in the LUCAS-2 group.
Long-term cost-effectiveness (Markov model)
The cost-effectiveness estimates were extrapolated over a lifetime time horizon using the Markov model.
The lifetime cost-effectiveness results obtained with the model are presented in Table 24. The base-case
analysis is based on a cohort of patients aged 60 years, followed over 40 years, which corresponds to the
average age of patients who survived at 1 year. Results suggest that the LUCAS-2 device is dominated
by manual CPR, with an incremental cost of £2376.40 and an incremental QALY of –0.1286. This finding
is robust to a range of sensitivity analyses as shown in Table 24.
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FIGURE 14 Cost-effectiveness plane for the LUCAS-2 device compared with manual chest compression. Complete-case
analysis based on 1000 bootstrap replications.
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FIGURE 15 Cost-effectiveness plane for the LUCAS-2 device compared with manual chest compression. MI analysis
based on 1000 bootstrap replications.
TABLE 24 Incremental cost-effectiveness ratios from lifetime analysis
Analysis
Incremental
ICERCost (£) QALY
Base-case analysis (aged 60 years cohort) 2376.40 –0.1286 Manual CPR dominates
One-way sensitivity analyses
Sensitivity to costs
+20% of costs 2851.60 –0.1286 Manual CPR dominates
–20% of costs 1901.10 –0.1286 Manual CPR dominates
Sensitivity to QALY
+20% of QALY 2376.40 –0.1543 Manual CPR dominates
–20% of QALY 2376.40 –0.1029 Manual CPR dominates
Sensitivity to 1-year mortality
+20% 1-year mortality –3987.50 –0.0187 £213,014 per QALY
–20% 1-year mortality 10,603.80 –0.2401 Manual CPR dominates
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Figure 16 shows the results from the probabilistic sensitivity analysis that takes parameter uncertainty into
account. The CEAC indicates that the probability that the LUCAS-2 device is cost-effective is only around
20%, irrespective of the value of λ.
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FIGURE 16 Cost-effectiveness acceptability curves for the LUCAS-2 device compared with manual CPR.
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Chapter 6 Discussion
Summary of main results
This pragmatic, cluster randomised trial found that the introduction of the LUCAS-2 device into routine
ambulance service use did not improve outcomes after OHCA. There was no improvement in survival to
30 days or survival with a CPC score of 1 or 2. We did not identify any treatment-modifying variables,
although there was a suggestion that the LUCAS-2 device might be more effective in patients with initial
rhythms of PEA or asystole. In a systematic review, including the five existing trials of mechanical chest
compression, there was no evidence of an advantage to mechanical chest compression for any outcomes,
including survival and survival with good neurological function.
The findings of worse neurological outcomes and lower survival in patients presenting with an initially
shockable rhythm was unexpected. Although these analyses were defined a priori, they were not the
primary objective of the trial and should be interpreted with caution and deemed as hypothesis
generating. One of these hypotheses is that interruptions in CPR during device deployment could cause
reduced cardiac and cerebral perfusion. Alternatively, slightly more patients received adrenaline after
randomisation in the LUCAS-2 group than in the control group, which might increase cardiac instability
and impair cerebral microcirculation. Finally, deployment of the LUCAS-2 device before the first shock is
likely to have led to a delay in the time to first shock, which might, in itself, reduce survival.19
Strengths and limitations
This was a pragmatic study designed to assess the effectiveness of the LUCAS-2 device when implemented
in a real-life setting. The intention of the trial was to test the LUCAS-2 device in an environment that was
similar to the introduction of a new technology into the NHS.
We chose to use a cluster randomised design with vehicles as the unit of randomisation. The major advantages
of this design were that it made implementation of the trial for participating ambulance service staff as simple
as possible and it allowed inclusion of eligible cardiac arrests because recruitment was not dependent on a
paramedic making a decision to randomise. This meant that one of the major potential drawbacks of cluster
randomisation – selection bias – was avoided. Similarly, the design allowed recruitment to proceed quickly,
and we successfully recruited nearly 4500 patients in 38 months. Selection bias could still be possible with this
design, if there was a lower threshold for initiation of resuscitation if a LUCAS-2 device was present, although
this potential bias could occur with any design and is not limited to cluster randomisation. The independent
DMC monitored possible selection biases throughout the trial, by looking at the proportions of patients
resuscitated when the LUCAS-2 device and control vehicles were first on scene and the characteristics of
patients recruited to the two trial groups. There was no evidence of any substantial selection bias.
Our approach to training staff in use of the new technology was pragmatic and reflected the training that
would be delivered when rolling out new technology across UK ambulance services. The training package
was developed and delivered by experienced ambulance training staff. In the UK, the average ambulance
paramedic encounters only one or two cardiac arrests per year and CPR update training is provided annually,
so it is unlikely that, if the LUCAS-2 device was introduced into routine service, individuals would have
extensive opportunities to practice with it and become expert in its use. The success of implementation is
particularly important when considering the potential benefits and harms of mechanical chest compression,
as interruptions in CPR and delays in device deployment are a major factor that can impact on outcomes.
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Non-compliance in the LUCAS-2 arm was a major feature of this study: only 985 (60%) of 1652 patients
randomly assigned to the LUCAS-2 group received mechanical chest compression. We expected that the
LUCAS-2 device would not be used in approximately 15% of cases. These were situations in which use of
the LUCAS-2 device would be impossible or inappropriate and would occur in clinical practice as often as
they occurred in the trial. This includes patients who were too large or too small for the device, cases
when the device malfunctioned, situations in which physical space restrictions or constraints made the use
of the LUCAS-2 device impossible and cases in which a solo responder was first on scene and did not have
the LUCAS-2 device. This usually occurred because the initial emergency call was not for cardiac arrest, so
the LUCAS-2 device was not part of the equipment that would be initially taken to the patient. However, a
significant proportion of non-uses of the LUCAS-2 device occurred for reasons that were related to the
conduct of a research project and would not arise in normal clinical practice. These included the crew not
having been trained in the trial procedures the LUCAS-2 device having been removed from the vehicle and
errors by the crew about the study protocol.
The sample size was increased to maintain the power of the study to compensate for non-compliance
in the LUCAS-2 arm. We also performed CACE analyses to investigate whether or not non-compliance
affected the estimates of the treatment effect in the primary ITT analysis. The CACE analyses suggested
that, if anything, outcomes were worse if the LUCAS-2 device was actually used and did not suggest that
non-compliance had obscured a treatment benefit.
We attempted to measure the quality of CPR provided during the trial resuscitation attempts, in both the
manual and LUCAS-2 arms. Unfortunately, this ultimately proved impossible. Our initial plan was to download
electrocardiography (ECG) recordings from defibrillators, but this proved impossible because of the different
models of defibrillator in use in the four ambulance services, their different data recording capabilities
and the logistics of ensuring that the recordings were downloaded and stored at the appropriate time. We
also attempted to use the data automatically recorded by the LUCAS-2 devices to verify their use during
resuscitations. This was unsuccessful because of the difficulty of extracting data from the devices (it could be
done only at the periodic servicing points) and the difficulty of reconciling the times and dates on the LUCAS-2
device recordings with the ambulance service records of the times and dates of resuscitation attempts. The
data on performance of ambulance service personnel on the manikins may not be representative of the quality
of CPR under field conditions.
The economic analysis was primarily based on data that were collected alongside the trial, which improves
internal validity. In addition, linkage with large administrative data sets, including the HES data, was used
to obtain resource use estimates that are more accurate than those obtained using retrospective surveys
of patients. Of course, the long-term decision model relied on a number of assumptions and existing
evidence was scarce for some parameters. We are confident, however, that it captured the most relevant
relative costs and outcomes of the LUCAS-2 device compared with manual CPR. It is worth noting that a
value of information analysis was not conducted, as the cost-effectiveness results were robust to a wide
range of assumptions and the uncertainty around the dominance of manual CPR over the LUCAS-2 device
was low (also, the key parameter of the model – the effectiveness of LUCAS-2 – was derived from the best
possible source of evidence).
Other evidence
The systematic review of mechanical chest compression included five randomised trials, involving
> 10,000 participants. The combined treatment effect did not suggest benefit to mechanical chest
compression and no individual study found benefit. The results for survival with good neurological
outcome were heterogeneous and both CIs and prediction intervals were wide and did not rule out
benefit in some trials.
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One important difference between the PARAMEDIC trial73 and other industry-sponsored trials70,71 was that
they included elements that differed from routine practice. These included more intensive initial and
re-training, a run-in period,71 and, in one study a threshold for quality of implementation, whereby patients
were excluded if the threshold was not attained.
Another key difference between this and other recent trials was the absence of CPR feedback technology
in the participating ambulance services. CPR feedback devices allow the measurement and adjustment of
CPR quality.96 Although international guidelines published in 2010 suggested that the devices could be
considered as part of an overall strategy to improve CPR quality,3 their adoption into clinical practice has
been variable. The scarcity of this technology limited our ability to report on the quality of CPR and
monitor the performance of our implementation strategy. These findings serve to highlight the potential
limitations of expecting the findings from efficacy trials to translate to real-life practice, for which the same
degree of rigour, attention and assessment does not apply.
One earlier mechanical chest compression trial, ASPIRE,55 found unfavourable results for survival and
neurological outcome, similar to the PARAMEDIC trial.71 It was suggested that these effects were largely due
to heterogeneity of treatment effects between sites and a re-analysis97 suggested that the unfavourable
outcomes may have been due to protocol changes at one trial site (of five). However, the study investigators
disagreed with this interpretation.98 The finding of a similar result on survival with good CPC score in the
PARAMEDIC trial71 gives some support to this finding.
Some of the other trials were successful in collecting at least some data on the quality of CPR provided
in their manual compression arms. In the CIRC trial,71 CPR quality data were collected from 96% of
participants and showed compression fractions in the first 5 minutes of 79.0% (SD 12.3%) in the manual
group and 74.7% (SD 12.7%) in the mechanical arm. The target compression rates in the two arms of
this trial were different: 100/minute in the manual arm and 80/minute in the mechanical arm. The target
was achieved more often in the manual arm: median compression rate in the manual arm was 89.9
(IQR 79.3–100.3), but in the mechanical arm it was 65.9 (IQR 61.3–70.2). In LUCAS in Cardiac Arrest
(LINC),70 compression fraction was recorded from 10% of patients and was 84% in the mechanical
compression group and 78% in the manual group. The ASPIRE trial55 recorded compression fraction in the
first 5 minutes from 45% of the manual compression group and 52% of the mechanical compression
group; it was very similar, at 0.6 (SD 0.2) in the manual arm and 0.59 (SD 0.21) in the mechanical arm.
The remaining two trials did not report any information on CPR quality. Recording of CPR quality in the
context of a pragmatic trial is extremely challenging and may influence the trial’s interpretation. For
example, although the CIRC trial71 did not demonstrate benefit to mechanical chest compression and the
trial’s formal conclusion was equivalence (albeit with very wide boundaries for the definition of equivalence),
the fact that manual compression was provided well allowed the claim that the mechanical device was as
good as manual compression.
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Chapter 7 Conclusions
This trial and a meta-analysis of the results from RCTs that enrolled > 10,000 patients do not suggestthat mechanical chest compression devices are superior to manual chest compression when used
routinely during resuscitation after OHCA. An economic evaluation showed that the LUCAS-2 device was
unlikely to be cost-effective. The widespread deployment of devices based on clinical effectiveness does
not seem justified. It is possible that mechanical chest compression devices will continue to play a role in
resuscitation, as they can deliver chest compressions when manual CPR is difficult or impossible, such as
during ambulance transport, and are likely to be the best treatment option in such situations. They may
also have an important role in hospitals as a bridge to advanced treatments, such as extracorporeal
membrane oxygenation.
Recommendations for research
Mechanical chest compression devices have not been evaluated for CPR during ambulance transport
and further research is needed to establish whether or not there is any benefit in such situations.
The use of mechanical devices for in-hospital cardiac arrest has not been adequately evaluated in
randomised trials. The results of prehospital studies may not extrapolate to the in-hospital setting because
of differences in the patient population and response times, so further trials in this setting may be justified.
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Appendix 1 In-hospital data fields
Length of stay
Sedation status first 24 hours
Lowest temperature first 24 hours (surrogate for therapeutic
hypothermia)
Number of days of basic cardiovascular, respiratory, organ
support
Number of days advanced cardiovascular, respiratory, renal,
GI, neurological, dermatological, liver organ support provided
Treatment withdrawn status
Referral for organ donation
Actual organ donation
ICNARC CASE Mix – code
Date of admission DAH
Residence prior to admission to acute hospital RESA
Age DOB
Admission type PA _V3
Levels of care Level 3 days CCLOD
Level 2 days CCL2D
Level 1 days CCL ID
Level 0 days CCLOD
Date of ultimate discharge from ICU/HDU DUDICU
Date of discharge from your hospital DDH
Status at discharge from your hospital HDIS
Destination post discharge from your hospital DESTH V3
Residence post discharge from hospital RESD
Classification of surgery To identify any procedures CLASSNS
Date of death DOD
Date of ultimate discharge from hospital (If transferred to
another hospital)
DUDH
Status at ultimate discharge from hospital (If transferred to
another hospital)
UHDIS
Date of first critical care visit post discharge from your unit DFCCD
Critical care visit post discharge from your unit CCD
GI, gastrointestinal; HDU, high-dependency unit.
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Hospital Episode Statistics: PARAMEDIC – Data Extract Request
[V1.0: October 2012 (CK) – updated March 2013 (CK)]
Data required for study participants for 12 months following randomisation.
Hospital Episode Statistics: inpatient
Data fields Description
Admissions
Date of admission (admidate) This field contains the date on which the patient was admitted to hospital at the start
of a hospital spell; admidate is recorded on all episodes within a spell
Method of admission
(admimeth)
This field contains a code that identifies how the patient was admitted to hospital;
admimeth is recorded on the first and also all subsequent episodes within the spell
(i.e. where the spell is made up of more than one episode)
Source of admission (admisorc) This field contains a code that identifies where the patient was immediately prior to
admission. Most patients are admitted from home, but there are some significant
exceptions. In particular, this field differentiates between patients admitted from
home and patients transferred from another hospital provider or institution
Augmented/critical care period
ACP end date (acpend) This field gives the end date of a period of augmented care
ACP start date (acpstar) This field states the start date of a period of augmented care
High-dependency care
level (depdays)
This field contains the number of days of high-dependency care in a period of
augmented care
Intensive care level days (intdays) This field contains the number of days of intensive care in a period of augmented care
Number of ACPs within
episode (numacp)
This derived field gives the number of ACPs within episode
Clinical
All diagnosis codes (diag_nn) There are 20 fields (14 before April 2007 and seven before April 2002), diag_01 to
diag_20, which contain information about a patient’s illness or condition. The field
diag_01 contains the primary diagnosis. The other fields contain secondary/subsidiary
diagnoses. The codes are defined in the ICD-10
All operative procedure
codes (oper_nn)
There are 24 fields (12 before April 2007 and four prior to April 2002), oper_01 to
oper_4, which contain information about a patient’s operations. The field oper_01
contains the main (i.e. most resource intensive) procedure. The other fields contain
secondary procedures. The codes are defined in the tabular list of the Classification of
Surgical Operations and Procedures; the current version is OPCS-4. Procedure codes
start with a letter and are followed by two or three digits. The third digit identifies
variations on a main procedure code containing two digits. The third digit is preceded
by a full stop in OPCS4, but this is not stored in the field. A single operation may
contain more than one procedure
Patient classification (classpat) This field identifies day cases, ordinary admissions, regular day and regular
night attenders
Discharges
Date of discharge (disdate) This field contains the date on which the patient was discharged from hospital. It is
present in the record only for the last episode of a spell
Destination on
discharge (disdest)
This field contains a code that identifies where the patient was due to go on leaving
hospital. In most cases patients return home. For many patients the discharge
destination is the same as source of admission (admisorc)
Method of discharge (dismeth) This field contains a code that defines the circumstances under which a patient left
hospital. For the majority of patients this is when they are discharged by the
consultant. This field is completed only for the last episode in a spell
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Data fields Description
Episodes and spells
Date episode ended (epiend) This field contains the date on which a patient left the care of a particular consultant
Date episode started (epistart) This field contains the date on which a patient was under the care of a particular
consultant. If a patient has more than one episode in a spell, for each new episode
there is a new value of epistart. However, the admission date that is copied to each
new episode in a spell will remain unchanged and will be equal to the episode start
date of the first episode in hospital
Episode duration (epidur) This field contains the difference in days between the episode start date (epistart) and
the episode end date (epiend). If the episode is unfinished epidur is set as null
Episode order (epiorder) This field contains the number of the episode within the current spell. All spells start
with an episode where epiorder is 01. Many spells finish with this episode, but if the
patient moves to the care of another consultant then a new episode begins. Episode
numbers increase by 1 for each new episode until the patient is discharged (this
includes transfers to another NHS trust or PCT, i.e. the first episode in the new trust
will have epiorder 01). If the same patient returns for a different spell in hospital,
epiorder is again set to 01
Episode status (epistat) This field tells you whether or not the episode had finished before the end of the HES
data-year (i.e. whether the episode was still ‘live’ at midnight on 31 March). Because
hospital providers are advised not to include clinical data (diagnosis and operation
codes) in unfinished records, these are normally excluded from analyses. Also, if
unfinished episodes are included in time series analyses – when data for more than
1 year are involved – there is a danger of counting the same episode twice
HRGs
HES-generated HRG
version (hrg_n.n)
This HES-derived field contains HRG values. HES adds the two most recent versions of
HRG codes to records
NHS-generated HRG
code (hrgnhs)
The trust-derived HRG value as submitted to SUS takes into account the dominant
grouping procedure (domproc) and may differ from the HES-derived HRG (HRG_n.n)
Dominant procedure (domproc) Contains the dominant procedure (operation) code assigned as part of the (NHS) HRG
derivation process and submitted to SUS
Patient
Age at start of episode (startage) This derived field, calculated from episode start date (epistart) and date of birth (dob),
contains the patient’s age in whole years [from 1 to 115 (1990–1 to 1994–5) and
from 1 to 120 (1995–6 onwards)]
Patient identifier – HES-
generated (pseudo_hesid)
This field uniquely identifies a patient across all data-years. It is generated by matching
records for the same patient using a combination of NHS number, local patient
identifier, postcode, sex and date of birth
Sex of patient (sex) This field contains a code that defines the sex of the patient
Socioeconomic
IMD decile group (md04_decile) This field uses the IMD overall ranking to identify which 1 of 10 groups a super
output area belongs to, from most deprived through to least deprived
System
SUS record ID (susrecid) SUS-generated record identifier
ACP, augmented care period; HRG, health-care resource group; ICD-10, International Classification of Diseases, Tenth
Edition; IMD, Index of Multiple Deprivation; OPCS, Office of Population Censuses and Surveys; OPCS-4, OPCS Classification
of Interventions and Procedures version 4;PCT, primary care trust; SUS, Secondary Use Services.
DOI: 10.3310/hta21110 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 11
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Gates et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
79
Hospital Episode Statistics: outpatient
Data fields Description
Appointments
Appointment date (apptdate) The date when an appointment was scheduled
First attendance (firstatt) Indicates whether a patient is making a first attendance or follow-up attendance, and
whether the consultation was face to face or via telephone
Attendance type (atentype) A field derived from ‘first appointment’ (firstatt) and ‘attended or did not attend’
(attended), used to identify if the attendance occurred and whether it was the first
or subsequent
Attended or did not
attend (attended)
This indicates whether or not a patient attended for an appointment. If the patient did
not attend it also indicates whether or not advanced warning was given
Clinical
Diagnosis (diag_nn) There are 12 fields (two before April 2007), diag_01 to diag_12, which contain
information about a patient’s illness or condition. The field diag_01 contains the
primary diagnosis. The other fields contain secondary/subsidiary diagnoses. The codes
are defined in the International Statistical Classification of Diseases, Injuries and
Causes of Death
Main specialty (mainspef) A code that defines the specialty under which the consultant is contracted. Compare
with ‘treatment specialty’ (tretspef), the specialty under which the consultant worked
Treatment specialty (tretspef) This field contains a code that defines the specialty in which the consultant was
working during the period of care. It can be compared with mainspef, the specialty
under which the consultant is contracted. From April 2004, a new list of treatment
specialties was introduced (see below). The new list describes the specialised service
within which the patient was treated
Medical staff type seeing
patient (stafftyp)
Gives information about the type of care professional staff dealing with the patient
during a consultant outpatient attendance, or nurse or midwife contact
HRGs
NHS-generated HRG version
no. (hrgnhsvn)
The version number for NHS-generated HRG code (hrgnhs)
NHS-generated HRG
code (hrgnhs)
The NHS-generated HRG code takes into account the dominant grouping procedure
(domproc) and may differ from the HES-derived HRG (hrgorig)
Patient
Patient identifier – HES-
generated (pseudo_hesid)
This field uniquely identifies a patient across all data-years. It is generated by matching
records for the same patient using a combination of NHS number, local patient
identifier, postcode, sex and date of birth
Sex of patient (sex) This field contains a code which defines the sex of the patient
Socioeconomic
IMD decile group (md04_decile) This field uses the IMD overall ranking to identify which 1 of 10 groups a super
output area belongs to, from most deprived to least deprived
System
SUS record ID (susrecid) SUS-generated record identifier
HRG, Healthcare Resource Group; IMD, Index of Multiple Deprivation; SUS, Secondary Use Services.
APPENDIX 1
NIHR Journals Library www.journalslibrary.nihr.ac.uk
80
Hospital Episode Statistics: accident and emergency
Data fields Description
Attendances
Arrival mode (aearrivalmode) The mode by which a patient arrived at an A&E department
Arrival date (arrivaldate) The arrival date of a patient in the A&E department
Attendance category
(aeattendcat)
An indication of whether a patient is making an initial or follow-up attendance within
a particular A&E department:
1. first attendance
2. planned follow-up or
3. unplanned follow-up
Follow-up always refers to attendance at the same department, and for the same
incident as the first attendance
Attendance disposal
(aeattenddisp)
The way in which an A&E attendance might end
Department type (aedepttype) A classification of A&E department type according to the activity carried out
Clinical
A&E diagnosis (diag n) The A&E diagnosis code recorded for an A&E attendance. The CDS allows an
unlimited number of diagnoses to be submitted; however, only the first 12 diagnoses
are available within HES. The A&E diagnosis is a six-character code: diagnosis
condition (n2), subanalysis (n1), anatomical area (n2) and anatomical side (anl)
A&E investigation (invest n) The A&E investigation recorded for an A&E attendance. The CDS allows an unlimited
number of investigations to be submitted, however, only the first 12 investigations
are available within HES. The A&E investigation is a six character code made up of
investigation (n2) and local sub-analysis (up to an4). As the subanalysis is for local use,
it cannot be classified
A&E treatment (treat n) The A&E treatment recorded for an A&E attendance. The CDS allows an unlimited
number of treatments to be submitted; however, only the first 12 treatments are
available within HES. The A&E treatment is a six-character code made up of treatment
(n2), subanalysis (n1) and a local use section (up to an3). As the local use section is
used for local codes, it cannot be classified
HRGs
Dominant procedure (domproc) The procedure that the HRG grouping algorithm has identified as having the greatest
effect upon the resources consumed by a patient
Trust HRG value (hrgnhs) The trust-generated HRG code
Trust HRG version (hrgnhsvn) The version number for trust-generated HRG code (hrgnhs)
Patient
Age on arrival (arrivalage) This derived field, calculated from arrival date and date of birth
Patient identifier – HES
generated (pseudo_hesid)
This field uniquely identifies a patient across all data-years. It is generated by matching
records for the same patient using a combination of NHS number, local patient
identifier, postcode, sex and date of birth
Sex of patient (sex) This field contains a code which defines the sex of the patient
Residence
Patient’s PCT of
residence (respct06)
This derived field contains the code for the PCT for the area in which the patient lived
immediately before admission. It is derived from the patient’s postcode in the
field homeadd
Socioeconomic
IMD decile group (md04_decile) This field uses the IMD overall ranking to identify which 1 of 10 groups a super
output area belongs to, from most deprived to least deprived
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Data fields Description
System
Record identifier This is a record identifier that is created by the system. The eight digits store a
decimal number
SUS record ID (susrecid) SUS-generated record identifier
Treatment
Health authority of treatment
(hatreat)
Health authority of treatment. This field is derived from the hospital provider code
(procode). It indicates the health authority within which the treatment took place
PCT of treatment (pcttreat) PCT of treatment. It is derived from the main site postcode of the hospital provider
code (procode), indicating the PCT area within which the organisation that was
providing the treatment was located
Note: (1) The PCT itself may be the provider of the treatment and (2) care provided at
subsidiary sites will be attributed to the main trust location
CDS, Commissioning Data Set; IMD, Index of Multiple Deprivation; PCT, primary care trust; SUS, Secondary Use Services.
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Appendix 2 Training documents
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Version 1.1 01/11/2010 
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Version 1.1 01/11/2010 
 
Station   Date  
 
Number Element Achieved 
1 Student is able to state the eligibility criteria 
 
2 Student is able to state the exclusion criteria 
 
3 Student is able to state the randomisation method 
 
4 Student opens the bag and pushes ON for one second to start self test 
 
5 Student positions Back Plate - if part of crew requires cessation of CPR to position Back plate thereafter resumes manual CPR 
 
6 Student takes the LUCAS from bag, extend legs and ensure claw locks are open by pulling releasing rings.                                            
 
7 Student stop compressions & connects the LUCAS to the back plate – nearest side to operator first  
 
8 Student positions suction cup immediately over end of sternum and ensure it is centered over chest.                            
 
9 Student pushes suction cup to chest with 2 fingers ensuring the pressure pad is in contact with chest & holds in place 
 
10 With the suction cup still held in place, the student pushes PAUSE to lock in start position  
 
11 Student confirms correct placement                                         
 
12 Student activates LUCAS by pressing either ACTIVE (30:2) OR ACTIVE (continuous compressions) 
 
13 Student attaches hands free defibrillation pads (ensuring wires are not under suction cup) 
 
14 Student attaches the stabilisation strap  
 
15 Student secures arms with wrist straps 
 
16 After 2 minutes student pauses LUCAS to check rhythm  
 
17 
Student states that if non-shockable then restart LUCAS 
                                      OR 
If shockable, restarts LUCAS, charges defibrillator, performs 
safety checks and delivers shock while LUCAS is running 
 
18 Student changes suction cup after use 
 
19 Student describes how to clean LUCAS if contaminated 
 
20 Student describes how to manage patient records after each case 
 
21 Student describes what actions are to be taken in the event of an adverse or unexpected event 
 
 
 
Student Name   Assessor Name  
 
Signature   
 
Signature  
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Appendix 3 Event reporting
1. Event Details (Complete as applicable): 
Date of Event 
(dd/mm/yyyy)  Device serial No          
Crew 
IDs/names: 
 Station 
Name: 
 
Vehicle Call 
Sign: 
 
Date of cardiac 
arrest: 
(dd/mm/yyyy) 
 Case No:  Patient DoB 
(dd/mm/yyyy) 
 
CRF05: Event Form                         
 
  
 
Event affecting patient         Event affecting crew  
 
March 2012 Version 2.0
Please fax or email 
 within 24hrs of notification of event 
2. Description of Event  
(Please continue on separate sheet as necessary) 
 
 
 
3. Follow up Information 
 
 
Resolved? Y   N         Date resolved ________ 
4. Reason for Reporting (all patients in this trial will be in an immediately life threatening situation; death or 
hospitalisation is certain.  The options below should only be ticked if they were clearly caused by the event.) 
Death Y   N   
Life-threatening event Y   N   
In-patient hospitalisation or prolongation of existing hospitalisation Y   N   
Persistent or significant disability/incapacity Y   N   
Other medically significant reason for reporting Y   N   
If other please specify .. 
. Notified by (signature)  Print Name  
Date of Report dd/mm/yyyy    
OFFICE USE ONLY      Event No:    
Was the event an ADE Yes  No    
Was the event an SADE? Yes  No Was the event related? Yes  No  
Was the event an Incident? Yes  No Was the event unexpected Yes  No  
Checked by clinical reviewer:            Device Failure? Yes  No  
Date of review:            User error? Yes  No  
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Appendix 4 Case report forms
 
PART 1 – COMPLETE THIS FORM FOR 1st EMERGENCY VEHICLE ON SCENE 
  Completed from: Paper A3   PRF   Paper A4   PRF     CAD   E- PRF  
 Scanned  A3 PRF    
  
Date of cardiac arrest (dd/mm/yyyy): ____/____/______  Case No: _____________  Station: ___________________ 
  
Call Sign (of 1st emergency vehicle on scene): _____________     LUCAS  CONTROL Non trial vehicle  
  
If other resource 1st on scene: Bike  HEMS  Com 1st responder  Unmarked vehicle  None  
  
999 Call Time          :           :                                 At Scene Time           :           :                 At Patient Time           :                   
(CAD) (24hr)             (hh)         (mm)         (ss)                                 (CAD) (24hr)                  (hh)         (mm)          (ss)                                                     (hh)         (mm)  
  
Please indicate which crew were on the 1st emergency vehicle on scene, if known:  
Crew name 1: _____________________ 1st on scene  Crew name 3: _____________________ 1st on scene         
  
Crew name 2: _____________________ 1st on scene  Crew name 4: _____________________ 1st on scene  
1. Key Data
a) Resuscitation attempted by EMS: Y    N   
(1st vehicle on scene)  
 If no: i)   Incompatible with life Y   N  
 ii)  DNAR or expected death Y  N  
 iii) Futility (>15mns since collapse + Y  N  
      no bystander CPR + asystole >30s)   
b) Patient presumed ≥18: Y  N  
c) DOB: ____/____/______    or       Unknown  
(dd) (mm)    (yyyy)
     i) If unknown - approx. age:  
 d) Female               Male        
 e) Patient believed: Not pregnant     Pregnant   
2. Aetiology (tick one only) 
  
Presumed Cardiac  
Traumatic
Respiratory
Submersion
Unknown*
Other* (non cardiac)
  
*Specify:  
3. Location 
Home   
Public place 
Other*  
*Specify (e.g. Ambulance, Friend’s house):
4. Witness/Bystander  
  
a) Witnessed:  
  
 Y  N  Unknown  
    
 If yes: 
  Bystander  
 EMS  
 Non EMS healthcare     
 b) Bystander CPR before 
 EMS arrival:  
 (general public, GP/nurse, off duty health care) 
  
 Y  N   Unknown  
  
c) Defib before EMS arrival: 
  
 Y  N   Unknown  
PART 2 – ONLY COMPLETE IF PATIENT IS ELIGIBLE 
5. Compliance LUCAS used:  Y   N                    
 If no: TBC   Protocol confusion*  Patient too big   Other*   
  Not trained  Crew decision*   Patient too small  *Specify: _________ 
Forgot   No device*   Device failure*    ________________ 
 6. Resuscitation Information 
a) Initial rhythm:  VF   VT   PEA   Asystole   Unknown  
b) Drugs given (for CA):  Y  N   Unknown   
c) Intubated  (successfully): Y   N    Unknown       
d) LMA/Supraglottic device (successfully): Y N        Unknown  
7. Outcomes  
 a) ROSC at any time:  Y  N  Unknown       
 b) Transported to Hospital (with CPR/ROSC): Y   N (deceased)  
 i) If no - CPR stopped at hh/mm (24hr)              : 
 
 ii) If yes - Time Left Scene hh/mm/ss (24hr)           :          :  iii) Hospital name:_____________________ 
        (transporting vehicle)     (CAD) 
 iv) Destination time (CAD) hh/mm/ss (24hr)           :          :  v) Handover time hh/mm (24hr)            :            
                 (transporting vehicle)                                                                   (transporting vehicle) 
 vi) Status at handover: ROSC  CPR in progress   Unknown  
 vii) Patient declared deceased by ED staff: Y  N (complete CRF02)  Unknown (complete CRF02)  
only one)  
(select  
8. Comments 
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Checks to make: 
1. Date of cardiac arrest (dd/mm/yyyy): ____/____/______ Case No: _________ Station: __________
2. Patient Details      Not known   
    First names: _____________________________ Last name: ____________________________________     
    Address:   ______________________________________________________________________________ 
    Postcode:    __________________    NHS No (from SCR):  
  
  
3. Date SCR checked (dd/mm/yyyy): 1. ____/____/______ Record found?  YES   NO  
               
     2. ____/____/______ Record found?  YES   NO  
  
4. GP Details known?   YES          NO   
  
    GP name: ___________________________ Surgery name: _________________________________ 
  
    GP address: _______________________________________________  Post code: __________________ 
  
    GP phone number: _____________________________ Date of GP contact (dd/mm/yyyy): ____/____/______  
  
5. Date registrar contacted (dd/mm/yyyy): 1. ____/____/______ 2. ____/____/______ Not checked  
  
6. Date hospital contacted   (dd/mm/yyyy): 1. ____/____/______    2. ____/____/______ Not checked   
  
7. Date of discharge from hospital: ____/____/______ Date of discharge from ICU: ____/____/______ 
  
Discharged to: Home  Nursing/residential home Rehab facility  Other__________ 
Address: __________________________________________________ Post code: __________________
     
(other than home) 
  
8. MRIS (WCTU only) - Date of upload onto MRIS (dd/mm/yyyy):   
Outcome: 
  
9. Death recorded?  YES   NO  
  
    If yes, date of death (dd/mm/yyyy): ____/____/______ Unknown  
  
    Location of death: Unknown  Hospital  Home  Other  Specify: _____________ 
  
    Source: SCR  GP Registrar  Hospital      MRIS  Other   Specify: _____________ 
      (Tick all that apply) 
If “No death recorded”, send information sheet 1 (invite letter):
  
  
10. Date information sheet 1 sent (dd/mm/yyyy): ____/____/______ 
 Date reply received (dd/mm/yyyy): ____/____/______ Type of reply: Post  Phone  Email  
 If no reply within 14 days:  write  call  patient  
 11. Date of 2nd contact (dd/mm/yyyy): ____/____/______ 
 Date reply received (dd/mm/yyyy): ____/____/______ Type of reply: Post  Phone  Email  
  
12. Comments (record details of phone conversation): 
  
  
  
  
13. If no reply within 14 days, action taken: Contact GP  SCR check  Registrar  Phone patient   
     Date (dd/mm/yyyy): ____/____/____ Response: _________________________________________________ 
  
14. Consultee required? (If YES, complete CRF07) YES   NO   Unknown  
        
Version 2.1 Jun 2011 Please fax to WCTU:   
____/____/______
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Appendix 5 Three-month follow-up
questionnaires
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Mobility 
I have no problems in walking about   
I have some problems in walking about  
I am confined to bed  
  
Self-Care 
I have no problems with self-care  
I have some problems washing or dressing myself  
I am unable to wash or dress myself  
  
Usual Activities (e.g. work, study, housework, family or 
leisure activities) 
I have no problems with performing my usual activities  
I have some problems with performing my usual activities  
I am unable to perform my usual activities  
  
Pain/Discomfort 
I have no pain or discomfort  
I have moderate pain or discomfort  
I have extreme pain or discomfort  
  
Anxiety/Depression 
I am not anxious or depressed  
I am moderately anxious or depressed  
I am extremely anxious or depressed  
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SF-12 forms have been redacted for copyright reasons.
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 Type of service
Which service have 
you used since your 
cardiac arrest? 
Please tick (√) yes or 
no
Total number of days 
spent  in 
hospital/convalescent or 
nursing home since your 
cardiac arrest
Total number of  
visits since your 
cardiac arrest
Hospital inpatient 
stay (in addition to 
your stay reported in 
question 1)
       Yes       No  
 
Hospital outpatient 
clinic        Yes       No  
 
Hospital accident 
and emergency 
department
Yes No
 
Nursing/residential 
home        Yes         No  
 
Other 
(please specify)       Yes        No  
 
1. Immediately following your cardiac arrest how many days did you spend in hospital?
Type of ward Total number of days
Intensive care unit  
Cardiac care unit
General ward  
2. Since that time have you used any of the following hospital based or residential care services 
(for example, have you been admitted to hospital again or had an outpatient clinic appointment)? 
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Appendix 6 Twelve-month follow-up
questionnaires
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Mobility 
I have no problems in walking about   
I have some problems in walking about  
I am confined to bed  
  
Self-Care 
I have no problems with self-care  
I have some problems washing or dressing myself  
I am unable to wash or dress myself  
  
Usual Activities (e.g. work, study, housework, family or 
leisure activities) 
I have no problems with performing my usual activities  
I have some problems with performing my usual activities  
I am unable to perform my usual activities  
  
Pain/Discomfort 
I have no pain or discomfort  
I have moderate pain or discomfort  
I have extreme pain or discomfort  
  
Anxiety/Depression 
I am not anxious or depressed  
I am moderately anxious or depressed  
I am extremely anxious or depressed  
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1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
Instruction to patient: Below is a list of problems and complaints that veterans sometimes have in response to stressful life  
experiences. Please read each one carefully, put an “X” in the box to indicate how much you have been bothered by that problem in 
the last month.
PCL-M for DSM-IV (11/1/94) Weathers, Litz, Huska, & Keane National Center for PTSD - Behavioral Science Division 
This is a Government document in the public domain. 
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Type of service
Which service have 
you used in the last 
three months? 
Please tick (√) yes 
or no 
 
Total number of days 
spent  in  
hospital/convalescent 
or nursing home in 
the last three months
Total number of visits 
in the last three 
months
Hospital inpatient 
stay         Yes            No
 
 
Hospital outpatient 
clinic         Yes            No
 
 
Hospital accident 
and emergency   
department
        Yes            No  
 
Nursing/residential 
home         Yes             No  
 
Other (please  
specify) 
  
  
 
        Yes             No  
 
  
1. Over the last three months have you used any of the following hospital based or residential care 
services (for example, have you been admitted to hospital or had an outpatient clinic appointment)?
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Type of service
Have you used the     
service in the last three 
months?  Please tick (√) 
yes or no 
Total number of face to 
face contacts over the 
last three months
a.  GP, surgery visit           Yes                 No  
b. GP, home visit           Yes                 No  
c. District nurse, health visitor or 
member of community health team 
          Yes                 No  
d. Social worker           Yes                  No  
e. Counsellor           Yes                  No  
f. Home help or care worker            Yes                  No  
g. Speech and language therapist           Yes                  No  
h. Psychiatrist or psychologist           Yes                   No  
i. Day centre           Yes                    No  
j. Lunch or social club (organised by 
health or social care providers)           Yes                    No  
k. Food, medicine or laundry       
delivery service (organised by 
health or social care providers)
          Yes                    No  
l. Family or patient support or self 
help groups           Yes                    No  
m. Other (please specify, for       
example have you had any    
telephone consultations with 
your GP):
 
 
 
 
 
                          
          Yes                    No
 
2.   Over the last three months have you used any of the following community based health and 
social services (this includes any services that are not within the hospital for example, visits to 
the GP)?  
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MMSE forms have been redacted for copyright reasons.
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Appendix 7 Data management plan
PARAMEDIC Data Management and Monitoring Plan 
• 
• 
• 
• 
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2. Data Cleaning, data checking and monitoring at WCTU 
2.1 New Data Clerks 
2.2 Checks during 
2.3 Checks on entered data for CRF01 
• 
• 
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2.3.1 On-going Quarterly logic/data checks 
 
 
 
 
 
 
 
 
 
 
2.3.2 On-going Monthly logic/data checks 
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2.4 Checks on data entered on database for CRF02  
2.4.1 Primary Outcome 
• 
• 
• 
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• 
2.4.2 Monthly logic checks 
• 
• 
•
2.4.3 Other data on CRF02 
2.5 Crew names/training details 
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2.6 Inbuilt database validation 
1.1 2.7 Validation/Range checks 
2.8 Follow-up Questionnaires 
2.8.1 Data Checking at WCTU (data entered on database against paper forms) 
2.9 Oversight arrangements 
2.9.1Trial Management Group 
2.9.2 Trial Steering Committee  
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Appendix 8 Statistical analysis plan
Statistical Analysis Plan 
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Appendix 9 Systematic review search strategy
MEDLINE search strategy
1. exp Heart Arrest/
2. exp Death, Sudden/
3. cardiac arrest.tw.
4. heart arrest.tw.
5. cardiopulmonary arrest.tw.
6. sudden cardiac death$.tw.
7. sudden death$.tw.
8. or/1-7
9. exp Cardiopulmonary Resuscitation/
10. Heart Massage/
11. cpr.tw.
12. cardiopulmonary resuscitation.tw.
13. chest compression$.tw.
14. resuscitat$.tw.
15. or/9-14
16. Cardiopulmonary Resuscitation/is [Instrumentation]
17. autopulse.tw.
18. auto-pulse.tw.
19. thumper.tw.
20. lucas.tw.
21. hands-free.tw.
22. (pneumatic adj10 (pump or device)).tw.
23. (pneumatic adj10 compression$).tw.
24. (automat$ adj10 compression$).tw.
25. (device$ adj10 compression).tw.
26. (mechanical adj10 compression$).tw.
27. (machine$ adj10 compression$).tw.
28. piston$.tw.
29. load distributing.tw.
30. (vest adj10 compression).tw.
31. (mechanical adj10 cpr).tw.
32. (pneumatic adj10 cpr).tw.
33. (device adj10 cpr).tw.
34. (machine$ adj10 cpr).tw.
35. (vest adj10 cpr).tw.
36. or/16-35
37. 8 and 15 and 36
38. randomised controlled trial.pt.
39. controlled clinical trial.pt.
40. randomized.ab.
41. placebo.ab.
42. drug therapy.fs.
43. randomly.ab.
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44. trial.ab.
45. groups.ab.
46. 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45
47. exp animals/ not humans.sh.
48. 46 not 47
49. 37 and 48
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Appendix 10 End-of-study information sheet
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